 
 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
1 Phase 1 Randomized , Placebo -Controlled , Dose -Escalation 
Study  of the Safety , Reactogenicity , and Immunogenicity  of 
Trivalent  Salmonella  (S. Enteritidis /S. Typhimurium /S. Typhi 
Vi) Conjugate V accine against Invasive Salmonella  Disease 
Administered Parenterally to Healthy U.S. Adults   
 
Protocol Number: Salmonella  conjugates CVD 1000  
 
Clinical Principal Investigator: Wilbur H. Chen , MD , MS  
Center for Vaccine Development  and Global Health  
University of Maryland School of Medicine  
685 West Baltimore Street, Suite 480  
Baltimore, MD 21201, U.S.A.  
 
IND Sponsor: University of Maryland, Baltimore  
IND Sponsor ’s Representative : Myron M. Levine, MD, DTPH  
Center for Vaccine Development  and Global Health  
University of Maryland School  of Medicine  
University of Maryland, Baltimore  
685 West Baltimore Street, Suite 480  
Baltimore, MD 21201 , U.S.A.  
 
In Collaboration With:  Bharat Biotech  International Ltd.  
Hyderabad, India  
 
Funding Source: The Wellcome Trust  
London, UK  
 
 
Version 10.0 
25 February  2021 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 2 - STATEMENT OF COMPLIANCE  
This trial is to be conducted in accordance with Good Clinical Practices (GCP) as required by 
the following:  
• United States Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 54, 21 CFR Part 56, and 21 CFR Part 312)  
• International Conference on Harmonization (ICH) E6; 62 Federal Register 25691 (1997)  
• The Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule -Final 
Modification (45 CFR  Parts 160 and 164)  
• The local laws and regulations, which prevail over the University of Maryland, Baltimore  
Compliance with these standards provides public assurance that the rights, safety, and well -
being of study subjects are protected, consistent with t he principles that have their origin in the 
Declaration of Helsinki.  
All key personnel (all individuals responsible for the design and conduct of this trial) have 
completed Human Subjects Protection Training.  
 
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 3 - SIGNATURE PAGE  
The signature below constitut es the approval of this protocol and the attachments, and provides 
the necessary assurances that this trial is to be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal a nd 
regulatory requirements and applicable United States of America federal regulations and ICH 
guidelines.  
 
Principal Investigator:  _________________________________________________  
 Name / Title (Print)  
Signature:  _________________________________________________  
Date:  _________________________________________________  
 
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 4 - Table of Contents  
Statement of Compliance  ................................ ................................ ................................ ......................  2 
Signature Page  ................................ ................................ ................................ ................................ ..... 3 
Abbreviations  ................................ ................................ ................................ ................................ ........  6 
Protocol Synopsis  ................................ ................................ ................................ ................................ . 8 
Key Personnel ................................ ................................ ................................ ................................ ..... 11 
1 Background ................................ ................................ ................................ ................................ .... 12 
1.1 Epidemiology and  Burden of Disease  ................................ ................................ ..............  12 
1.2 Vaccine Development  ................................ ................................ ................................ ..... 12 
1.3 Pre-clinical Testing  ................................ ................................ ................................ ..........  14 
1.3.1  Rabbit non -GMP product study  ................................ ................................ ........  14 
1.3.2  GLP Toxicology Study  ................................ ................................ ......................  16 
1.4 Clinical Studies  ................................ ................................ ................................ ...............  16 
1.5 Risks and Potential Benefits  ................................ ................................ ............................  17 
1.5.1  Risks ................................ ................................ ................................ ................  17 
1.5.2  Potential Benefits  ................................ ................................ .............................  18 
2 Study Design  ................................ ................................ ................................ ................................ . 19 
2.1 How the Trivalent Conjugate Vaccine is expected to be used in sub -Saharan Africa  ........  20 
2.2 Work flow of the Phase 1 stu dy in U.S. adults ................................ ................................ .. 21 
2.3 Primary Objectives and Outcome Measures  ................................ ................................ .... 23 
2.4 Secondary Objectives and Outcome Measures  ................................ ...............................  23 
2.5 Exploratory Objectives and Outcome Measures  ................................ ..............................  23 
3 Study Population  ................................ ................................ ................................ ............................  25 
3.1 Inclusion Criteria  ................................ ................................ ................................ .............  26 
3.2 Exclusion Criteria  ................................ ................................ ................................ ............  26 
3.3 Enrollment and Randomization Procedures  ................................ ................................ ..... 28 
3.3.1  Re-screening procedure  ................................ ................................ ...................  28 
3.4 Withdrawals and Discontinuation from Study  ................................ ................................ ... 28 
4 Investigational Products  ................................ ................................ ................................ .................  30 
4.1 Description of Investigational Products  ................................ ................................ ............  30 
4.1.1  Trivalent, with preservative (multi -dose vials) ................................ ....................  30 
4.1.2  Placebo ................................ ................................ ................................ ............  30 
4.2 Formulation, Storage, Packaging, and Labeling  ................................ ...............................  30 
4.2.1  Trivalent, with preservative (multi -dose vials) ................................ ....................  30 
4.2.2  Placebo ................................ ................................ ................................ ............  30 
4.3 Preparation and Administration  ................................ ................................ .......................  30 
4.4 Study Product Accountability  ................................ ................................ ...........................  31 
4.5 Masking of the Study Product  ................................ ................................ ..........................  31 
5 Study Procedures ................................ ................................ ................................ ...........................  32 
5.1 Clinical Evaluations  ................................ ................................ ................................ .........  32 
5.2 Clinical Laboratory Evaluations  ................................ ................................ .......................  32 
5.3 Research Laboratory Assays ................................ ................................ ...........................  33 
6 Study Schedule  ................................ ................................ ................................ ..............................  34 
6.1 Screening Visit (Day -45 till -2) ................................ ................................ ........................  34 
6.2 Visit 1 - Enrollment & Vaccination Dose #1 (Day 1) ................................ ..........................  34 
6.3 Visit 2 Follow Up (Day 2)  ................................ ................................ ................................ . 35 
6.4 Visit 3 Follow Up (Day 8 ±1) ................................ ................................ ............................  35 
6.5 Visit 4 Follow Up (for Cohorts A -B) or Vaccination Dose #2 (for Cohorts C and D) (Day 
29 ±3) ................................ ................................ ................................ .............................  35 
6.6 Visit 5 Follow Up, only for Coho rt C and D (Day 36 ±1) ................................ ....................  36 
6.7 Follow Up, Visit 5 for Cohort A -C, Visit 6 for Cohort C and D (Day 57 ±3) ........................  36 
6.8 Final Follow Up, Visit 6 for Cohort A -B (Day 180 ±14), Visit 7 for Cohort C and D (Day 
210 ±14) ................................ ................................ ................................ .........................  36 
6.9 Unscheduled Visits ................................ ................................ ................................ ..........  37 
6.10  Early Termination  ................................ ................................ ................................ ............  37 
7 Assessme nt of Safety ................................ ................................ ................................ .....................  38 
7.1 Specification of Safety Parameters  ................................ ................................ ..................  38 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 5 - 7.2 Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters ...........  38 
7.3 Halting Rules  ................................ ................................ ................................ ..................  40 
7.4 Safety Oversight  ................................ ................................ ................................ .............  40 
8 Assessment  of Immunogenicity  ................................ ................................ ................................ ...... 42 
8.1 Enzyme -linked Immunosorbent Antibody Assay (ELISA)  ................................ .................  42 
8.2 Opsonophagocytic Activity (OPA) assay  ................................ ................................ ..........  42 
8.3 Serum Bactericidal Activity (SBA) assay  ................................ ................................ ..........  42 
8.4 Antibody Secreting Cells (ASC) assay  ................................ ................................ .............  42 
8.5 Circulating B cell memory cells (BM) and Cell -mediated Immunity (CMI) (cytokines, T 
cell effector and memory (including circulating T follic ular/helper cells -cTfh-), T cell 
homing ................................ ................................ ................................ ............................  43 
8.6 Antibodies in Oral Fluid  ................................ ................................ ................................ ... 43 
9 Quality and Monitoring  ................................ ................................ ................................ ...................  44 
9.1 Quality Control and Quality Assurance  ................................ ................................ ............  44 
9.2 Clinical Monitoring  ................................ ................................ ................................ ...........  44 
9.3 Site Monitoring Plan  ................................ ................................ ................................ ........  45 
10 Statistical Considerations  ................................ ................................ ................................ ...............  46 
10.1  Study Hypothesis and Sample Size Considerations  ................................ .........................  46 
10.1.1  Sample size in Part 2 of the study  ................................ ................................ .... 46 
10.2  General Statistical Principles  ................................ ................................ ...........................  46 
10.3  Go/No -Go Milestones ................................ ................................ ................................ ...... 47 
11 Ethics/Protection of Human Subjects  ................................ ................................ ..............................  48 
11.1  Ethical Standard ................................ ................................ ................................ ..............  48 
11.2  Institu tional Review Board  ................................ ................................ ...............................  48 
11.3  Informed Consent Process  ................................ ................................ ..............................  48 
11.4  Exclusion of Women, Minorities, and Children (Special Populations)  ...............................  49 
11.5  Subject Compensation  ................................ ................................ ................................ .... 49 
11.6  Subject Confidentiality  ................................ ................................ ................................ ..... 49 
11.7  Future Use of Stored Specimens  ................................ ................................ .....................  50 
12 Data Handling and Record Keeping ................................ ................................ ................................  51 
13 Publication Policy  ................................ ................................ ................................ ...........................  52 
14 References  ................................ ................................ ................................ ................................ .... 53 
Appendix A: Schedule of Events (Cohort A -B) ................................ ................................ .....................  57 
Appendix A: Schedule of Events (Cohort C and D)  ................................ ................................ ..............  58 
Appendix B: Clinical Laboratory Values, for Study Eligibility  ................................ ................................ . 59 
Appendix C: Grading Scales for Laboratory Toxicity and Reactogenicity ................................ ..............  60 
  
 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 6 - ABBREVIATIONS  
ADH Adipic acid dihydrazide  
AE Adverse Event  
ALT Alanine aminotransferase  
ALS Antibodies in lymphocyte supernatant  
ANC Absolute neutrophil count  
ASC Antibody secreting cells  
AST Aspartate Aminotransferase  
BM B memory cell  
Bn Naïve B cell  
BMI Body mass index  
BP Blood pressure  
BUN Blood urea nitrogen  
CBC Complete blood count  
CDAP  1-cyano -4-dimethylaminopyridinium tetrafluoroborate  
CFR Code of Federal Regulations  
CFU Colony forming units  
cGMP  Current Good Manufacturing Practices  
CI Confidence interval  
CMI Cell-mediated immunity  
COPS  Core -O polysaccharide  
COVID -19 Coronavirus disease 2019, caused by the SARS -CoV-2 virus  
CRF Case report form  
CRP C-reactive protein  
cTfh Circulating T follicular/helper cell  
CVD Center for Vaccine Development  
ELISA  Enzyme -linked immunosorbent assay  
ELISPOT  Enzyme -linked immunospot  
FDA Food and Drug Administration  
FliC Flagellin subunit protein (phase 1  for S. Typhimurium ) 
GCP  Good Clinical Practice  
GLP Good Laboratory Practice  
GMBS  succinimidyl 4 -maleimidylbutyrate   
(a.k.a. N -γ-maleimidobutyryl -oxysuccinimide ester)  
GMT  Geometric mean titer  
HBsAg  Hepatitis B surface antigen  
HCV Hepatitis C virus  
HEENT  Head, eyes, ear, nose, throat  
Hg Hemoglobin  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HRP Horseradish peroxidase  
HSF1  Health Sciences Facility building 1  
ICF Informed consent form  
IDS Investigational Drug Service  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 7 - ICH International Conference on Harmonization  
IgA Immunoglobulin A  
IgG Immunoglobulin G  
IM Intramuscular  
IND Investigational new drug  
iNTS  Invasive non -typhoidal Salmonella  
IP Investigational product  (a.k.a. study product)  
IRB Institutional Review Board  
ISM Independent safety monitor  
IU International units  
KDO  2-keto-3-deoxyoctonate  
LPS Lipopolysaccharide  
mcg or µg  Micrograms  
mL Milliliters  
MOP  Manual of procedures  
NTS Non-typhoidal Salmonella  
OPA Opsonophagocytic activity  
OPS O polysaccharide  
PBS Phosphate buffered saline  
pH Potential of hydrogen  
PBMC Peripheral blood mononuclear cells  
PI Principal investigator  
QA Quality assurance  
QC Quality control  
QMP  Quality management plan  
S. (italicized  S.) Salmonella , bacteria of the genus  
SAE Serious adverse event  
SBA Serum bactericidal activity  
SD Standard deviation  
SFC Spot-forming cell  
SMC  Safety monitoring committee  
SOP  Standard operating procedure  
TBIL  Total bilirubin  
TLR5  Toll-like receptor 5  
TT Tetanus toxoid  
U.S. or U.S.A.  United States (of America)  
WBC  White blood cell  
WHO  World Health Organization  
 
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 8 - PROTOCOL SYNOPSIS  
Title:  Phase 1 Randomized, Placebo -Controlled, Dose -Escalation Study of the 
Safety, Reactogenicity, and Immunogenicity of a Trivalent (S. 
Enteritidis/S. Typhimurium/ S. Typhi Vi) Conjugate Vaccine against 
Invasive Salmonella  Disease Administered Parenterally to Healthy U.S. 
Adults  
Phase:  1, adaptive design  
Population:  104 healthy adults, ages 18 through 45 
Site:  Two site, outpatient trial   
Subject 
Participation 
Duration:  Each s ubject  will participate for approximately 6-7 months from the time of 
enrollment through completion of the study.   
Investigational 
Products : • Study product # 1: trivalent  S. Enteritidis  [25 µg]/S. Typhimurium  [25 
µg]/S. Typhi Vi conjugate vaccine , presented in multi -dose vials 
containing 2-phenoxyethanol  preservative . 
• Study product # 2: placebo , a buffer containing the 2-phenoxyethanol 
preservative . 
 
Primary 
Objectives:  
 1. Safety and Reactogenicity : To assess the frequency and severity of 
solicited local (i.e., injective site) and systemic (such as fever) AEs during 
the first 7 days following each dose of vaccine.  
2. Safety: To assess the frequency and severity of unsolicited AEs within 28 
days of each  dose of vaccine and the occurrence of any SAEs through 6 
months after the last dose of vaccine  
3. Immunogenicity: To measure the p roportion of subjects that achieve a 
four-fold increase in titer, as compared to baseline, of specific serum IgG 
anti-COPS ( S. Enteritidis or S. Typhimurium), anti -Vi (S. Typhi) 
polysaccharide, and anti -FliC (S. Enteritidis or S. Typhimurium) antibody 
at days 29 and 57, as measured by ELISA.  
Secondary 
Objectives  1. Safety: To assess the frequency and severity of abnormalities in clinical 
safety laboratory parameters at 7 days following the first dose of vaccine.  
2. Immunogenicity: To measure the proportion of subjects that achieve a 
four-fold increase in titer, as compared to baseline, of specific serum IgG 
anti-COPS  (S. Enteritidis or S. Typhimurium), anti -Vi (S. Typhi) 
polysaccharide, and anti -FliC (S. Enteritidis or S. Typhimurium) antibody 
at day  180/210 , as measured by ELISA.  
3. Immunogenicity: To calculate the GMT of serum IgG anti -COPS  (S. 
Enteritidis or S. Typhimurium ), anti -Vi polysaccharide, and anti -FliC (S. 
Enteritidis or S. Typhimurium ) antibodies at days 1, 29, 57, and 180/210, 
as measured by ELISA.  
 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 9 - Exploratory 
Objectives  1. Immunogenicity: To measure the titers of functional antibodies by serum 
bactericidal antibody (SBA) activity assay and opsonophagocytic activity 
(OPA) assay against S. Typhimurium, S. Enteritidis, and S. Typhi 
bacterial cells at days 1, 29, 57, and 180/210.  
2. Immunogenicity: To measure the antibody  secreting cells (ASC), specific 
for anti -COPS, Vi, FliC, and TT; possibly including homing markers and 
the measurement of antibodies in lymphocyte supernatants (ALS)  
3. Immunogenicity: To measure memory B and T cells, specific for anti -
COPS, anti-Vi, anti-FliC, and anti-TT activity; including the B cell s that 
exhibit mucosal homing marker s integrin  α4β7 and /or the lymph node 
homing marker CD62L  
4. Immunogenicity: To conduct functional genomic and proteomic studies to 
further explore the immune response to vaccin ation.  
5. Immunogenicity: To measure the anti -Vi polysaccharide, anti -TT, anti -
COPS, and anti -FliC antibody levels in oral fluid at days 1, 29, 57, and 
18/210, as measured by ELISA (Cohorts C and D)  
 
Brief 
Description of 
Study Design  
 This is intended to be an adaptive design study .1 In Part 1 of the study , we 
will conduct  a double -blinded, randomized, placebo -controlled, dose -
escalation study. Participants will be sequentially enrolled into Part 1 of the 
study in three dose -escala ting steps (Steps 1-3, Cohorts A-C), consisting of 
fractional vaccine doses containing : 6.25 µg  (Step 1) , 12.5 µg  (Step 2) , or 25 
µg (Step 3) of each specific polysaccharide by weight. Within each step, 
participants will be random ly allocated to receive  a single dose of  trivalent 
conjugate  vaccine or  placebo . In Step 3, participants may receive one dose 
or two -doses, separated by 28 days, of the vaccine.  
Part 2  of the study is intended to expand the safety and immunogenicity data 
from a selected d ose level of the vaccine  (anticipated to be the 25 µg per 
conjugate dose level) . The target dose for this part of the study is to be 
informed by safety and immunogenicity data from the dose -escalation 
cohorts, with an intent to select the most promising im munogenic dose of the 
vaccine. Part 2  of the study will consist of a cohort of 60 participants wh o will 
be random ly allocated to receive  a blinded two -dose regimen in one of the 
following three  possible treatment groups :  
• a single dose of  the trivalent conjugate vaccine , followed by a dose of 
placebo 28 days later  (n=25); 
• two doses of trivalent conjugate vaccine , separated by 28 days (n=25); 
• or two doses of placebo , separated by 28 days  (n=10) .  
Special Notation: Due to the limited shelf-life of the vaccine, which is being determined by an 
ongoing stability testing plan, the availability of this pilot production lot of vaccine may be 
limited in time.  Furthermore, since March 2020 the global pandemic due to SARS -CoV-2 virus 
(causing COVID -19 infections) has significantly disrupted the ability to conduct this study.   
Therefore, the Step 3 (Cohort C) has been significantly revised such that both a single and two -
dose regimens  of the 25 µg dosage of vaccine  will be evaluated, albeit with  a very small 
sample size. This was originally intended to be evaluated with a large sample size in Part 2 
(Cohort D), but due to the extraordinary present circumstances, the revised design of the study 
is intended to provide similar information which is c rucial for the vaccine development plan.  
Furthermore, in order to provide some bridging immunogenicity data, a small number of 
participants in Cohort C will be randomized to receive either a single or two -dose regimen of 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 10 - the 12.5 µg dosage of the vaccine.  It is possible that Part 2 (Cohort D) will not be conducted, 
due to lack of vaccine.  
Furthermore, because of the COVID -19 situation, for Cohort A the follow -up visits at 6 months 
post-vaccination w ere conducted by phone call contact and thus the collection of specimens 
was unable to be conducted. For Cohort B , the follow -up visits at 2 months and 6 months post -
vaccination were conducted by phone call contact and thus the collection of specimens was 
unable to be conducted. Therefore for Cohort A and B participants, a single clinic visit for the 
collection of blood an d oral fluid will be requested to measure the long -term immune responses 
(>6 months post -vaccination).  
Pharmaron CPC, Inc. (Baltimore, MD) is being added as a site for the enrollment of Cohort C.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 11 - KEY PERSONNEL  
Principal Investigator:  
Wilbur H. Chen, MD, M S, FACP, FIDSA  
Professor of Medicine  
Chief, Adult Clinical Studies section  
Center for Vaccine Development & Global Health  
University of Maryland School of Medicine  
Direct Office Phone: 410 -706-1188  
Mobile Phone: 443 -414-4462  
Email: wchen@som.umaryland.edu   
 
Clinical Co -Principal Investigator:  
Mohamed Al -Ibrahim, MB, ChB, FACP  
Pharmaron CPC Inc.  
800 W. Baltimore St., 5th Floor  
Baltimore MD 21201  
Office: (410) 706 -8772  
Cell: (4 10) 245-6888  
Email: Mohamed.al -ibrahim@pharmaron -us.com  
 
Immunology Co-Investigator s 
Marcela F. Pasetti, PhD  
Professor of Pediatrics and Microbiology & Immunology  
Direct Office Phone: 410 -706-2341  
Email: mpasetti@som.umaryland.edu  
 
Marcelo B. Sztein, MD  
Professor of Pediatrics , Medicine,  and Microbiology & Immunology  
Direct Office Phone: 410 -706-2345  
Email: msztein@som.umaryland.edu   
 
 
 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 12 - 1 BACKGROUND  
1.1 Epidemiology and Burden of Disease  
Salmonella enterica  serovars Typhi and Paratyphi A and B and certain non -typhoidal 
Salmonella enterica  (NTS) serovars are important causes of invasive Salmonella  disease 
worldwide .  “Typhoid Fever” is caused by Salmonella enterica  serovar Typhi ( S. Typhi) , while  
“Paratyphoid Fever” is caused by Salmonella enterica  serovar Paratyphi A ( S. Paratyphi A) or 
Salmonella enterica  serovar Paratyphi B ( S. Paratyphi B). Both Typhoid Fever and Paratyphoid 
Fever manifest as persistent fevers, abdominal discomfort, headache  and malaise . Without 
prompt and effective antibiotic treatment , these infections may lead to intestinal hemorrhage,  
intestinal  perforation and peritonitis, myocarditis, hepatitis, neurological consequences and 
death.  In the pre -antibiotic era the case fatality rate of typhoid fever was circa 15%.  
In industrialized countries in North America, Europe  and in Australia  and New Zealand , various 
NTS serovars are commo n causes of gastroenteritis, as the  result of sporadic food-borne 
transmission or associated with outbreaks.  In older children and adults, t hese NTS infections  
typically result in uncomplicated diarrheal illness that does not require antibiotic treatment  and 
invasive infections due to NTS serovars in healthy adults are rare. However, among certain sub -
populations (such as infants < 3 months  of age , the elderly, and immun ocompromised  hosts ) in 
industrialized countries , invasive NTS (iNTS) infections  such as bacteremia, septicemia, and 
meningitis can be observed  and are associated with notable case fatality .2,3 The most common 
Salmonella  serovars associated with invasive disease in the U.S. include: S. Typhimurium, S. 
Enteritidis, S. Heidelberg, S. Dublin, and S. Schwarzengrund.4  
Whereas i nvasive disease due to NTS (bacteremia, septicemia, meningitis, etc.) is relatively 
rare in the US A and industrialized countries, a recognized burden of iNTS disease exists in sub -
Saharan Africa, where it was recently estimated that ~2 million cases (~227 cases/100,000 
infants and young children) occur annually.5  The case fatality ratio of iNTS disease in Africa is 
~20% , resulting in an estimated ~681,000 deaths each year.5 In sub -Saharan Africa f our 
serovars, S. Typhimurium, S. Enteritidis, I:4,[5],12:i -, and S. Dublin , account for > 85 -95% of all 
iNTS cases.6,7 Notably, the strains of S. Typhimurium, I:4,[5],12:i - and S. Enteritid is associated 
with i nvasive NTS disease in sub -Saharan Africa are genomically distinct from strains of those 
serovars circulating in the USA and Europe.8,9 For example, S. Typhimurium and I:4,[5],12:i - 
strains in the USA and Europe are overwhelmingly of multi -locus sequence type ST19, whereas 
the African strains are ST313, an unusual MLST type. Similarly, the S. Enteritidis strains in 
Africa are genomically distinct. Notably, most cases of iNTS in infant s and toddlers in sub -
Saharan Africa do not present with or have a history of gastroenteritis. The vast majority of the 
iNTS isolates from sub -Saharan Africa encode resistance to multiple clinically -relevant 
antibiotics .8,10    
1.2 Vaccine Development  
To address this important public health problem, iNTS vaccines  are being develop ed.11,12 The 
polysaccharides of encapsulated bacteria (e.g., Haemophilus  influenzae  type b, Streptococcus  
pneumoniae , Neisseria  meningitidis ) linked to carrier proteins have resulted in safe, 
immunogenic (in young children)  and highly effective parenteral polysacch aride conjugate 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 13 - vaccines.  One t yphoid polysaccharide conjugate vaccine , Typbar -TCV®, manufactured by 
Bharat Biotech, Hyderabad, India, that was first licensed in India , was pre -qualified in 2017 by 
the World Health Organization (WHO) for procurement by Un ited Nations Ag encies and its use 
in infa nts as young as six mo nths of age has been recommended by WHO’s Scientific Group of 
Experts (SAGE) .13,14 In contrast, currently there are no licensed NTS vaccines.  
CVD investigators have been developing candidate polysaccharide protein conjugate vaccin es 
for the prevention of iNTS  disease .  The vaccine development strategy involves targeting two 
surface virulence antigens of the key NTS Salmonella  serovars  including the core 
polysaccharide and O-polysaccharide (COPS) plus FliC protein, the unpolymerized  flagellin  
subunits of flagella  motility organelles .12,15-19   
The outer membrane lipopolysaccharide s of Salmonella  can be  divided into  3 distinct regions: 
an endotoxin  lipid A moiety;  a highly conserved , core oligosaccharide region; and a serogroup -
specific, repeating oligosaccharide  polymer ( O-polysaccharide [OPS]). The majority of human 
invasive isolates fall antigenically within Salmonella  group A  (includes S. Paratyphi A) , Group B 
(includes  S. Paratyphi B , S. Typhimurium  and I:4,[5],12:i -), Group C (includes S. Paratyphi C, S. 
Choleraesuis  and S. Newport ), and  Group D (includes S. Typhi , S. Enteritidis  and S. Dublin ).  
Serovars of Salmonella  serogroups A, B, and D share  a common mannose -rhamnose -galactose 
trisaccharide backbone. Distinct dideoxyhexose sugars linked to the mannose residues of the 
common side chain provide serogroup specificity. Thus, if the dideoxyhexose sugar  linked to the 
mannose is a paratose , this results in immunodominant antigen “2”, denoting a serogroup A 
Salmonella  isolate . If the sugar linked to the mannose is an abequose, this results in an 
immunodominant antigen “4”, denoting serogroup B Salmonella . Finally, if the sugar linked to 
the m annose is a tyvelose, this results in immunodominant antigen “9”, denoting serogroup D 
Salmonella .12  
Specific antibod y responses against the O polysaccharide antigens of the conjugate , if 
protective,  should provide some degree of protection against all the different serovar pathogens 
within that O serogroup. For example, both S. Enteritidis and S. Dublin serovars fall wi thin O 
serogroup D. Immune responses against Group D O antigen should contribute to protection 
against both of these Group D serovars. CVD investigators have devised practical methods to 
purify COPS from attenuated “reagent strains” that have been engineer ed to enhance the yield 
of COPS and to facilitate  the large -scale manufacture of these antigens  under enhanced 
occupational safety .18  The vaccine candidates to be  evaluated in this study are based on the 
COPS of S. Typhimurium (a Group B serovar) and S. Enteritidis  (a Group D serovar) . 
The S. Enteritidis conjugate component in our trivalent vaccine is generated by 1 -cyano -4-
dimethylaminopyridinium tetrafluoroborate  (CDAP) chemistry to link S. Enteritidis COPS to the 
FliC Phase 1 flagellin protein subunits of S. Enteritidis that had been derivatized with adipic acid 
dihydrazide ( ADH ) using carbodiimide. This  strategy is similar to the approach used for 
MenAfriVac™, which is comprised of the group A meningococcus capsular polysaccharide 
linked to tetanus toxoid (TT) .20 MenAfriVac has been administered to infants, toddlers, children, 
and adults in countries within the African Meningitis belt.21 CDAP linkage and ADH derivitization 
are also used by GlaxoSmithKline ( GSK ) Vaccines in preparing their multivalent pneumococcal 
conjugate vaccine (Synflorix™) and by Sanofi Pasteur Vaccines in preparing their quadrivalent 
meningococcal conjugate vaccine (Menactra™). Synflorix™ and Menactra™ have  extensive 
track records of safety in infants, children and adults, including in sub -Saharan Africa. Similarly, 
experimental S. Paratyphi A conjugates generated at the National Institute of Child Health and 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 14 - Human Development by John B. Robbins and colleagu es in the late 1990s consisted of S. 
Paratyphi A COPS linked to tetanus tox oid carrier protein and utilized ADH as a linker with 
CDAP conjugation .22 The S. Paratyphi A conjugates prepared by the Robbins La boratory at 
NICHD were safe and immunogenic in Phase 1 and Phase 2 clinical trials  that involved adults, 
teenagers and children 2 -4 years of age .23 Interestingly, among the pre -school age children who 
received either one or two spaced doses of S. Paratyphi A conjuga te 6 weeks apart , there was 
no evidence of a booster effect following administration of the second dose of conjugate.23   
The S. Typhimurium conjugate component in our trivalent vaccine is generated by modification 
at the polysaccharide terminal 2 -keto-3-deoxyoctonate (KDO) carbonyl with an aminooxythiol 
linker. The aminooxy forms an oxime bond with the KDO ketone that is further reduced with 
sodium cyanoborohydride. S. Typhimurium FliC protein  (phase 1 flagellin subu nit) is derivatized 
with the amine reactive reagent succinimidyl 4 -maleimidylbutyrate (GMBS) to introduce a 
maleimide moiety that is then linked to the reactive sulfhydryl of the derivatized COPS molecule 
via formation of a thioether bond. There is no FDA -licensed conjugate vaccine for human use 
that utilizes the specific method of conjugation employed for our S. Typhimurium 
glycoconjugate. However, a synthetic Hib capsul ar polysaccharide -based glyconjugate vaccine 
that is licensed and manufactured in Cuba (and that is pre -qualified by the WHO) utilize s a 
maleimide linker.24 We have extensive pre -clinical experience with S. Typhimurium conjugate 
vaccines prepared utilizing this approach, and have published reports that document the 
tolerability and immunogenicity of such conjugates in animal models.15,16,19,25 John Robbins and 
team at the NI CHD also successfully used aminooxy linker based approaches for synthesis and 
preclinical evaluation of COPS -based conjugates for a variety of gram -negative pathogens.26,27 
The S. Typhi conjugate component in our trivalent conjugate vaccine is essentially Typbar -
TCV™, a Vi conjugate va ccine generated by carbodiimide -mediated modification of S. Typhi Vi 
polysaccharide with ADH  that introduces reactive hydrazide groups that are then used to link to 
tetanus toxoid (TT) via a second carbodiimide step. Typbar -TCV is a licensed typhoid vaccin e in 
India and a number of other countries and has been extensively used in pediatric and adult 
populations.28 The World Health Organization conferred pre-qualification status for Typbar -TCV 
on January 3, 2018.14,29 It is now a vaccine which can be procured by United Nations agencies.   
Therefore, CVD investigators have devised novel candidate core -O polysaccharide -flagellin 
protein conjugates as a vaccine strategy for preventing iNTS  and we have combin ed the iNTS 
conjugates with a Vi-TT conjugate (Typbar -TCV) to create a Trivalent Conjugate vaccine for 
preventing invasive iNTS disease and typhoid fever . 
1.3 Pre-clinical Testing  
Early non -GMP formulati ons of monovalent S. Enteritidis and S. Typhimurium COPS:FliC 
conjugate vaccines were immunogenic and protected mice against fatal infections with the 
homologous serovar NTS pathogen.15-19  
1.3.1  Rabbit non -GMP product study  
Non-GMP bivalent and  trivalent formulations of the Salmonella  conjugate vaccines were also 
evaluated in a rabbit model.15 New Zealand White rabbits were immunized with 3 sequential 
doses of a monovalent S. Enteritidis, bivalent S. Enteritidis/Typhimurium, and trivalent S. 
Enteritidis/Typhimurium/Typhi conjugate vaccine formulat ions, separated 14 days apart, and 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 15 - serum was collected pre -vaccination and post -final immunization (at day 44). High titers of 
serogroup -specific anti -COPS and anti -Vi (in the trivalent formulation) IgG antibodies were 
elicited by the bivalent and trivalen t formulations; robust anti -FliC antibody were also elicited but 
the responses to FliC were lower relative to the anti -COPS titers. (Figure below)  
 
In vitro  functional antibody activity was demonstrated with the complement -mediated serum 
bactericidal acti vity (SBA) assay.  Furthermore, in vivo  functional antibody activity was 
measured with outbred CD -1 mice which were passively immunized with pooled pre - or post -
vaccination rabbit sera or PBS; then subsequently challenged intraperitoneally with S. Enteriti dis 
R11 or S. Typhimurium D65 (representative virulent Malian blood serovar isolates). Mice which 
received PBS or pre -vaccination sera demonstrated >90% fatality with S. Enteritidis and ~63% 
fatality with S. Typhimurium, whereas mice that received post -vaccination serum were protected 
against lethal challenge (vaccine efficacy ~88% for S. Enteritidis and 100% for S. Typhimurium). 
The Kaplan -Meier survival curves for the respective pre - and post -immune sera were compared 
using log -rank analysis and P values were calculated as <0.0001 for both serovar challenges.15 
(Figure below)  
 

Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 16 - 1.3.2  GLP Toxicology Study  
As part of our submission of an Investigational New Drug Application (IND) to the U.S. Food and 
Drug Ad ministration  (FDA) , the four products manufactured at Bharat Biotech International, Inc. 
and t wo of which are to be tested in the Phase 1 trial described herein have been evaluat ed in a 
Rabbit Toxicology Test performed by Noble Life Sciences, a Contract Re search Organization 
located in Sykesville, Carrol County, MD, that specializes in performing animal toxicology tests 
under the tenets of Good Laboratory Practices (GLP). Eighty pathogen -free rabbits, 40 males 
and 40 females , were injected ; 20 rabbits with each vaccine test  product (3 vaccine  test 
products : single -dose bivalent, multi -dose bivalent, and multi -dose trivalent ) and 20 with the 
placebo  test product  (buffer containing 2 -phenoxyethanol). The Rabbit Toxicology stud y was 
initiated July 20, 2018 and the first dose of study vaccines were administered on August 13, 
2018; a total of four sequential doses separated by 28 days was administered. All animals 
survived to the scheduled necropsy . There were no test article -related adverse changes in 
mortality, clinical observations, physical exams, injection site scores, body weights, food 
consumption, organ weights, organ -to-body weight ratios, body temperature, ophthalmology or 
urinalysis.  The antigen -specific ELISA IgG respo nses following the first dose of vaccine for the 
20 rabbits that received the trivalent multi -dose test article are shown in the table below.  
According to these pre -clinical data, the vaccines appear to be immunogenic after a single dose.  
ELISA IgG respons e following the first dose of vaccine for rabbits that received the trivalent multi -dose vaccine  
Typhimurium titers (EU/mL)    Enteritidis titers (EU/mL)    Typhi Vi titers (EU/mL)   
   GMT, pre  3.4     GMT, pre  7.2     GMT, pre  24.0 
   GMT, post (day 29)  1454.2      GMT, post (day 29)  4381.4      GMT, post (day 29)  2409.5  
   Geometric Mean Fold -rise 426.8      Geometric Mean Fold -rise 610.6      Geometric Mean Fold -rise 99.7 
   Minimum fold -rise 41.0     Minimum fold -rise 75.6     Minimum fold -rise 12.5 
   Maximum fold -rise 6977.1      Maximum fold -rise 3202.8      Maximum fold -rise 337.5  
1.4 Clinical Studies  
No prior human clinical studies have been performed with the trivalent  (iNTS conjugates 
combined with Typhoid  Vi conjugate ) candidate Salmonella  vaccines, that will be evaluated in 
the study  described in this clinical protocol .  
However , the S. Typhi Vi capsular polysaccharide -TT conjugate vaccine (Typbar -TCV®, Bharat 
Biotech, Hyderabad , Indi a) component is licensed as a monovalent conjugate vaccine  in India28 
and has been pre -qualified by the WHO and recommended by the WHO SAGE for use in 
adults, children and i nfants as young as 6 months of age .  Among the adverse effects 
associated with Typbar -TCV are the following:30 
• Common ( ≥1% and <10%): fever, pain at injection site, and swelling  
• Uncommmon ( ≥0.1% and <1%): injection site tenderness, itching, arthralgia, cold, 
cough, vomiting, and myalgia  
The iNTS conjugate s in our trivalent vaccine use Phase 1 flagellin  subunits from the 
homologous iNTS  serovars as the carrier protein. Flagellin can act as a n adjuvant through 
binding to Toll -like receptor 5 (TLR5) and the induction of innate and adaptive immune signaling 
via an MyD88 -dependent pathway and an MyD88 -indep endent mechanism.31,32 Genetically -
engineered fusion proteins consisting of influenza virus hemagglutinin or matrix protein  fused to 
a TLR5 stimulating portion of the FljB flagellin subunit of S. Typ himurium Phase 2 flagella have 
been evaluated in clinical trials . Some dose levels were associated with reactogenicity and 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 17 - elevated levels of C -reactive protein , suggesting strong stimulation of the innate immune 
system .33-35 Importantly, t he method of linkage of the Phase 1 flag ellin FliC subunits to COPS in 
our NTS conjugates mask s the TLR5 stimulating portion of flagellin. Pre-clinical assays of our 
conjugates have demonstrated >100 -fold reduction in TLR5 activity using an NF -κB-luciferase 
reporter assay.  Most importantly, rabbits tolerated the vaccine without mounting febrile 
responses or exhibiting elevated C -reactive protein levels following vaccination in the rabbit 
toxicology test.  
There is considerable justification for our expectation that a 25 µg (by wei ght of polysaccharide  
per dose of each conjugate ) dose of our iNTS conjugate vaccine will be safe and immunogenic , 
based on results with various Vi conjugate vaccines containing 25 µg of Vi linked to various 
carrier proteins . As mentioned, Typbar -TCV, whic h contains 25 µg of Vi polysaccharide linked to 
TT, has an excellent safety record in adults, children and infants.28  
In a field trial in Vietnam involving children  2-5 years  of age , a two-dose regimen of a nother Vi  
conjugate vaccine consisting of 25 µg of S. Typhi Vi polysaccharide linked to recombinant 
exotoxin A of Pseudomonas aeruginosa as the carrier protein was well tolerated, immunogenic 
and significantly protective against confirmed typhoid fever .36  
1.5 Risks and Potential Benefits  
1.5.1  Risks  
Risks related to Bivalent or Trivalent vaccine:  
Since this is an investigational vaccine and has not been given to humans previously, the  risks 
assoc iated with administration are unknown. These vaccines  are killed and purified and will not 
cause Salmonella  infection . With an injectable vaccine , recipients may have fever, swelling, 
redness and pain at the injection site.  An allergic reaction, including anaphylaxis , could possibly 
occur. The Typhoid component of the trivalent vaccine is virtually the same as the licensed 
vaccine called Typbar -TCV™. This licensed vaccine is known to cause fever in 10% of children 
who receive it.  
Blood Drawing risks:  
Blood drawing is sometimes associated with pain at the site from which the blood is drawn, 
bruising, and occasional lightheadedness and rarely, fa inting or infection. Bruising at the site of 
blood drawing can be prevented by applying pressure for several minutes. To reduce the risk of 
infection, the area is wiped clean with alcohol and germ -free equipment  is used . It is the policy of 
the American Re d Cross that recipients of an experimental vaccine  may not be able to d onate 
blood for one year after r eceipt. 
Risks of Confidentiality:  
Efforts will be made to keep personal health information confidential. There is a small risk  of loss 
of confidentiality  by an unauthorized person viewing study participant  records. In order to maintain  
confidentiality, the PI and the study staff will store study records in a locked area of a  limited 
access locked office . Study records and samples will be coded with a  numbe r, not the participant’s  
name. Record s will be used by the FDA,  the data coordinating center  and monitoring group, CVD 
and the IRB only in connection with carrying out their obligations relating to the study, and every 
effort will be made to keep the recor ds as confidential as possible, within the limits of the law.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 18 - Risks to Pregnancy or Fetus:  
If a woman is pregnant or become s pregnant, this  research may hurt the  baby or the pregnancy 
in ways that  are unknown. Women of childbearing potential  must use birth  control to be sure that 
they do not become pregnant. The only  birth control methods that work well enough to be sure 
that women of childbearing potential  will not become pregnant are  oral contraceptives (“the pill”), 
intrauterine devices (IUDs), contracep tive implants under the  skin, or contraceptive injections, 
and condoms with foam.  
1.5.2  Potential Benefits  
Participants will not benefit directly from their participation in this study. However, their 
participation may help the investigators better un derstand the response to these Salmonella  
vaccine s and whether these  vaccine s will help to prevent the disease.  
 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 19 - 2 STUDY DESIGN  
Part 1.  The first part of the study will be conducted as a traditional first -in-human , double -
blinded, randomized, placebo -contr olled, dose -escalation study. This part of the  study is 
designed to assess the safety, reactogenicity, and preliminary immunogenicity of a single  
parenteral (i.e. , intramuscular) dose of a trivalent (S. Enteritidis/ S. Typhimurium /S. Typhi) 
conjugate vaccine in comparison to a placebo control consist ing of buffer  plus preservative  (2-
phenoxyethanol) . 
In total, a pproximately 44 healthy eligible participants will be sequentially enrolled into Part 1 of 
the study in three steps based on dose.  
In Step 1  (Cohort A) , 10 participants will be randomly allocated to one of two treatment groups 
to receive:  
• trivalent vaccine , 6.25 mcg of each COPS and Vi, in 0.125 ml volume (N=8) mixed 
with 0.375 ml of placebo (phosphate buffered saline + 2 -phenoxyethanol + Tween 80 
stabilizer) to reach a volume of 0.5 ml ; 
• or placebo , 0.5 ml volume (N=2).  
In Step 2  (Cohort B) , 12 participants will be randomly allocated to one of two treatment grou ps 
to receive:  
• trivalent vaccine , 12.5 mcg of each COPS and Vi, in 0.25 ml volume (N=10) mixed 
with 0.25 ml of placebo to reach a volume of 0.5 ml ; 
• or placebo , 0.5 ml volume (N=2).  
In Step 3  (Cohort C) , 22 participants will be randomly allocated to one of five treatment groups 
to receive:  
• one dose of trivalent vaccine , 25 mcg of each COPS and Vi, in 0.5 ml volume (N= 6); 
• one dose of trivalent vaccine, 12.5 mcg of each COPS and Vi, in 0.5 ml volume 
(N=4);  
• two doses of trivalent vaccine, 25 mcg of each COPS and Vi, in 0.5 ml volume (N=6);  
• two doses of trivalent vaccine, 12.5 mcg of each COPS and Vi, in 0.5 ml volume 
(N=4);  
• or placebo , 0.5 ml volume (N=2).  
Each of the escalated dosage cohorts is designed to be slightly larger in size in order to have a 
higher probability to detect potential reactogenicity with the increasing quantities of fla gellin, 
which is a component ( the protein c arrier of the NTS co njugate s), while increasing the number 
of subjects exposed in a step -wise fashion .   
Following collectio n of the 28 day post -vaccination clinical data and rapid measurement of 
serum IgG ELISA antibody levels , there will be an interim analysis of the safety and 
immunogenicity  in preparation for advancement to Part 2 of the study.   
Part 2. The second part of the study  is intended to expand the safety and immunogenicity data 
from a selected dose level of the vaccines .  The target dose for this part of the study will be 
informed by the reactogenicity data from Part 1 of the study with particular attention on the dose 
level of vaccine administered in Step 3 (administration of the highest dose) and by the 
immunogenicity data from the dose -escalation cohorts, with an intent to select the most 
immunogenic yet well -tolerated dose of the vaccine formulations. Based on experiences with 
existing licensed and unlicensed Vi conjugate vaccines, we anticipate that the trivalent 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 20 - conjugate vaccine containing 25 mcg of polysaccharide of each conjugate will likely be the most 
immunogenic dose  and will hopefully be as well-tolerated  as monovalent Vi conjugate vaccines . 
Part 2 of the overall study will intend to enroll 60 eligible participants  who will be randomized to 
one of three  possible treatment arms :  
• Trivalent conjugate vaccine followed 28 days later by a second dose of trivalent 
conjugate vaccine  (n=25); 
• Trivalent conjugate vaccine followed 28 days later by a dose of placebo  (n=25); 
• A dose of placebo followed 28  days later by a second dose of placebo  (n=10). 
2.1 How the Trivalent Conjugate Vaccine is expected to be used 
in sub -Saharan Africa  
By administration of a Trivalent Conjugate Vaccine , we will aim to prevent two distinct clinico -
epidemiologic forms of invasiv e salmonellosis that affect somewhat different age groups in sub -
Saharan Africa, including invasive disease (septicemia, bacteremia, meningitis, etc.) caused by 
certain non -typhoidal serovars (in particular , S. Typhimurium and its variants , and S. Enteriti dis) 
and typhoid fever caused by S. Typhi. The S. Typhimurium and S. Enteritidis conjugates in the 
Trivalent Conjugate Vaccine are in tended to prevent iNTS disease which exhibits a peak 
incidence from 6-23 months of age .7,37 The iNTS incidence drops somewhat in children 24 -35 
months of age and then falls further in those 36-47 months of age.7,37 Thus, to diminish the iNTS 
burden the Trivalent Conjugate Vaccine will have to be administered in early infancy to elicit 
immune responses in time to protect children 6 -11 months of age  when maternally -transferred 
antibodies will have w aned . The Typbar -TCV component of the Trivalent Conjugate  is intended 
to prevent typhoid fever , a disease that shows a low incidence in infancy  but rises in children 
age 24 months and often peaks in children 5 -9 years of age.   
The ultimate preferred regime n to administer the Trivalent Conjugate Vaccine will be de termined 
by analysis of the results of future Phase 2 clinical trials that will be carried out in infants and 
toddlers in sub -Saharan Africa  with the doses being administered at ages when infants and 
toddlers receive other vaccines within the schedule of the Expanded Program on Immunization 
(EPI).  Currently in sub -Saharan Africa, three doses of parenteral pentavalent vaccine 
(diphtheria and tetanus toxoids, whole cell pertussis vaccine, Haemophilus influenzae  type b 
conjugate and hepatitis B combination vaccine) are given to young infants at ~6, ~10 and ~14 
weeks of age; another parenteral vaccine administered at these visits is multivalent 
pneumococcal conjugate vaccine. In sub -Saharan Afri ca the initial measles containing vaccine 
is administered at ~9 months of age (along with yellow fever vaccine in certain countries). A 
second dose of measles containing vaccine is administered at ~15 months of age. Future 
Phase 2 studies in infants and to ddlers will compare the safety, immunogenicity, and practicality 
of spaced 2 -dose and 3 -dose regimens of Trivalent Conjugate Vaccine administered during 
infancy alone or during infancy and toddler age . Moreover, the compatibility of the Trivalent 
Conjugate  with concomitantly administered EPI vaccines  will have to be established .   
The purpose of the Phase 1 trial in U.S. adults is to gather preliminary safety and 
immunogenicity data t o pave the way for initiating future Phase 2 trials in sub -Saharan Africa.  
Part 2 of this  study in healthy U.S. adults offers a potential opportunity to determine whether at 
day 56 the anti -COPS and anti -Vi antibodies in participants of the two -dose regimen exhibit 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 21 - higher avidity and perhaps higher titers than the antibodies at day 56 in recipients of a single 
dose of Trivalent Conjugate Vaccine.  
Serological data demonstrate that a single dose of monovalent Typbar -TCV conjugate 
administered to Indian children 6 -23 months of age is highly immunogenic in stimulating Vi 
antibodies and the titers remain elevated for up to 5 years post  primary -immunization.  There are 
no published or public human data to dictate the serum antibody response to a conjugate 
vaccine co nsisting of COPS conjugated to a carrier protein. Moreover, adult humans  immunize d 
with a glycoconjugate vaccine of any sort typically mount a maximal antibody response after the 
first dose that is not boosted following administration of a second dose of glycoconjugate. 
Therefore, the main purpose of administering two-sequenti al doses of trivalent conjugate 
separated by 4 weeks is to evaluate whether a two -dose regimen presents an increased risk for 
reactogenicity when the second dose is administered. A second dose is not expected to 
increase anti -COPS titers in U.S. adults but it may perhaps increase antibody avidity.  
2.2 Work flow of the Phase 1 stud y in U.S. adults  
Eligible subjects will be screened, enrolled, and vaccinated at the CVD Outpatient Vaccine 
Clinic (located on the 4th floor of HSF1)  or Pharmaron (located in the UMB BioPark 1 building) .  
After the documentation of informed consent, subjects will be screened for eligibility ; eligible 
subjects will subsequently be enrolled and randomized to a treatment group.  On Day 1  (and 
Day 29, for participants in Cohort s C and  D), study product will be administered, in double -
blinded fashion, as a n intramuscular injection into the deltoid muscle. Following vaccination, 
there will be a 20 -minute post -vaccination observation period. Following each dose of study 
product, safety an d reactogenicity will be measured by a daily oral temperature and solicited AE 
reporting over the subsequent 7 days (via a 7 -day memory aid); unsolicited AE reporting will 
occur through 28 days following the last dose of vaccine.  The occurrence of any SAEs will be 
recorded through 6 months after the last dose of vaccine (Day 180 or 210, for participants in 
Cohort C and D). 
Subjects in Steps 1 -2 (Cohorts A -B) will complete four additional outpatient visits on Days 8, 29, 
57, and 180 (final visit).  Subjects  in Cohort s C and  D will complete five additional outpatient 
visits on Days 8, 29 (second dose of masked study product), 36, 57, and 210 (final visit). The 
recording of AE s and concomitant medication change information, the performance of a 
physical exam ( if indicated), and the collection of study -specific samples will be performed 
during these outpatient visits.  Clinical safety laboratory tests will be evaluated on Day 8.  The 
final study visit will be for the collection of SAE information (Day 180 or 210). 
After the completion of enrollment of each cohort, the safety data through 7 -days post -
vaccination are to be reviewed by an independent Safety Monitoring Committee (SMC). The 
SMC must provide approval prior to the enrollment of the subsequent dose -escal ating cohort. 
Immunology data may not be available at the times of these scheduled SMC reviews.  
In addition to the evaluation of safety, immunogenicity assessments are planned to evaluate the 
immune responses induced by the three different vaccine formulat ions.  The study, however, is 
not statistically powered to determine significance of any pre -specified difference.  Therefore, 
there was no formal sample size calculation, based on immunogenicity, as the basis for the 
designed study.  Nonetheless, the samp le size was chosen based on the number of subjects 
appropriate for a phase 1 study in which these vaccines have never been evaluated in humans.   
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 22 -   Schematic of Study Cohorts  
Cohort  Vaccine  Dose of each COPS and of 
Vi  (µg) No. 
Subject s Dose #1  Dose #2  Vaccination 
Days  
A 
(Step 1)  Trivalent  
Placebo  6.25 
0 8 
2 Vaccine  
Placebo  - 
- 1 
SMC review of available safety data through 7 -days post -vaccination before proceeding to the next dosage cohort  
B 
(Step 2)  Trivalent  
Placebo  12.5 
0 10 
2 Vaccine  
Placebo  - 
- 1 
SMC review of available safety data through 7 -days post -vaccination before proceeding to the next dosage cohort  
C 
(Step 3)  Trivalent  
Trivalent  
Trivalent  
Trivalent  
Placebo  25 
25 
12.5 
12.5 
0 6 
6 
4 
4 
2 Vaccine  
Vaccine  
Vaccine  
Vaccine  
Placebo  Vaccine  
Placebo  
Vaccine  
Placebo  
Placebo  1& 29*  
1 & (29)*  
1& 29*  
1 & (29)*  
1 & (29)*  
SMC review of available safety data through 7 -days post -vaccination before proceeding to  Part 2 of the study  
D 
(Expanded, confirmatory 
cohort ) Trivalent  
Trivalent  
Placebo  (highest, well -tolerated dose 
among cohorts  A-C) 25 
25 
10 Vaccine  
Vaccine  
Placebo  Vaccine  
Placebo  
Placebo  1 & 29*  
1 & (29)* 
1 & (29)* 
Total  N = 104  
* In cohort s C and  D, the trivalent vaccine will be administered as a single dose (day 1) or as a two -dose (days 1 and 29) regimen. In order to maintain 
the masking of study products, on day 29 a placebo will be administered when indicated by the parentheses.  
SMC , Safety Monitoring Committee  
 
Schematic of the Flow of the Cohort  enrollm ents and timing of SMC meetings : 
Part 1 
Step 1 (Cohort A)  
single 6.25 µg dose trivalent  
or single dose placebo  
 
[SMC Review ] 
  
 Step 2 (Cohort B)  
single 12.5 µg dose trivalent  
or single dose placebo  
  
 [SMC Review ]  
 
  Step 3 (Cohort C)  
single 25 µg dose trivalent  
or two -dose 25 µg dose trivalent  
or single 12.5 µg dose trivalent  
or two -dose 12.5 µg dose trivalent   
or single dose placebo  
 
   [Go/No -Go Decision for Part 2 based on interim safety and immunogenicity assessment s]  
  
[SMC Review ] 
 
Part 2 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 23 -    Cohort D  
Trivalent on day 1 , (placebo on day 29) ; 
Trivalent on day 1  and day 29 ; 
Or Placebo on day 1 and day 29  
 
2.3 Primary  Objectives and Outcome Measures  
The primary objectives and outcome measure of this study are the following:  
1. Safety  and Reactogenicity : To assess the frequency and severity of solicited local (i.e., 
injective site) and systemic (such as fever) AEs during the first 7 days following each dose o f 
vaccine.  
2. Safety: To assess the frequency and severity of unsolicited AEs within 28 days of each dose 
of vaccine and the occurrence of any SAEs through 6 months after the last dose of vaccine  
3. Immunogenicity: To measure the p roportion of subjects that achi eve a four -fold increase in 
titer, as compared to baseline, of specific serum IgG anti -COPS ( S. Enteritidis or S. 
Typhimurium), anti -Vi (S. Typhi) polysaccharide, and anti -FliC (S. Enteritidis or S. 
Typhimurium) antibody at days 29 and 57, as measured by E LISA.  
2.4 Secondary Objectives and Outcome Measures  
The secondary objectives and outcome measures of this study are the following:  
1. Safety: To assess the frequency and severity of abnormalities in clinical safety laboratory 
parameters at 7 days following the first dose of vaccine.  
2. Immunogenicity: To measure the proportion of subjects that achieve a four -fold increase in 
titer, as compared to baseline, of specific serum IgG anti -COPS ( S. Enteritidis or S. 
Typhimurium), anti -Vi (S. Typhi) polysacch aride, and anti -FliCn (S. Enteritidis or S. 
Typhimurium) antibody at day  180/210 , as measured by ELISA.  
3. Immunogenicity: To calculate the GMT of serum IgG anti -COPS  (S. Enteritidis or S. 
Typhimurium ), anti -Vi polysaccharide, and anti -FliC (S. Enteritidis or S. Typhimurium ) 
antibodies at days 1, 29, 57, and 180/210, as  measured by ELISA.  
2.5 Exploratory Objectives and Outcome Measures  
The exploratory objectives and outcome measures of this study include the following:  
1. Immunogenicity: To measure an tibodies by serum bactericidal antibody (SBA) activity assay 
and opsonophagocytic activity (OPA) assay against S. Typhimurium, S. Enteritidis, and S. 
Typhi at days 1, 29, 57, and 180/210 . 
2. Immunogenicity: To measure the antibody secreting cells (ASC), speci fic for anti -COPS, Vi, 
FliC, and TT; possibly including homing markers and the measurement of antibodies in 
lymphocyte supernatants (ALS)  
3. Immunogenicity: To measure memory B and T cells, specific for anti -COPS, Vi, FliC, and TT 
activity; including the pres ence of B cell homing markers as assessed by the expression of 
mucosal homing marker integrin  α4β7 and the lymph node homing marker CD62L  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 24 - 4. Immunogenicity: To conduct functional genomic and proteomic studies to further explore the 
immune response to vaccinat ion. 
5. Immunogenicity: To measure the anti -Vi polysaccharide, anti -TT, anti -COPS, and anti -FliC 
antibody levels in oral fluid at days 1, 29, 57, and 180/210, as measured by ELISA (Cohorts 
C and D)   
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 25 - 3 STUDY POPULATION  
The study population will include healthy a dult men and women ages 18 to 45 years, inclusive.  
Participants will be recruited from the local Baltimore -Washington DC population through 
established methods, to include: future -contact authorized CVD volunteer database, local 
advertisements, campus fly ers, and word -of-mouth.  Potential volunteers  who are interested in 
the study are instructed to call the CVD to receive further information about the study.  
The process of informed consent begins when a person  contacts the CVD for information about 
the st udy. CVD research staff receive these inquiries and read through an IRB -approved 
telephone script which describes basic information on the study topic, duration and number of 
visits, procedures, and eligibility criteria. No personal health information is solici ted and 
afterwards interested potential participants are given an appointment to attend an Orientation 
Session  for formal screening.  
At the Orientation Session , the consent process continues. CVD research staff provide a 
detailed description of all aspects  of the study, including the rationale and background, the 
public health significance, the procedures and schedule of visits, and a detailed discussion of 
the risks and the presence or absence of benefit to them, as appropriate. The prospective 
subject is given a copy the study consent form (without the signature page) and is encouraged 
to discuss his/her participation with family members or advisors before agreeing to sign the 
informed consent form and proceeding with any screening procedures. An intereste d volunteer 
may decide to participate in the study on a separate visit or may continue the consent process 
after the Orientation Session  is completed.  
A similar process of recruitment, pre -screening, and consenting process will be performed at 
Phamaron. Ph armaron will use their recruitment process which may include participants outside 
of the local Baltimore -Washington vicinity. Pharmaron will use their established methods of 
recruitment which will include their volunteer database, local advertisements, soc ial media, and 
other methods.  As part of the consenting process, Pharmaron research staff will provide 
detailed description of all aspects of the study, including rationale and background, the public 
health significance, the procedures and schedule of vis its, and a detailed discussion of the risks 
and the presence or absence of benefit to them. The recruitment materials will be UMB IRB 
approved.  
Once both the investigator and the volunteer are satisfied that all questions have been 
answered and the volunte er expresses the desire to participate, the volunteer will be allowed to 
sign the consent form. A copy of the signed consent document will be given to the participant.  
After the informed consent form is signed, a one -on-one private meeting with a member of  the 
study team is performed, to continue the process of informed consent.  A brief written 
examination is administered to assess the volunteer’s comprehension of the study (i.e., 
Comprehension Assessment Tool ). A passing score of ≥70% is required; wrong a nswers will be 
reviewed with the volunteer and examination may be re -taken once. Upon successful 
completion of the Comprehension Assessment Tool , the research staff can proceed with formal 
screening.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 26 - 3.1 Inclusion Criteria  
Subjects must meet all inclusion criteria in order to participate in the study:  
1. Ability to provide written informed consent  
2. Age 18 - 45 years, inclusive  
3. Good general health as determined by : vital signs (heart rate <100  bpm; blood pressure 
systolic > 90 mm Hg and ≤1 50 mm Hg; dias tolic >45  mm Hg and ≤90 mm Hg; oral 
temperature <100.4ºF), medical history, and a physical examination† within 45 days 
before administration of first dose of vaccine.  
† The intent is to evaluate for acute or ongoing chronic medical conditions which have b een 
present for 90 days or more and which could affect the assess of safety or immunogenicity. 
Chronic medical conditions should be stable for at least 60 days; defined as no 
hospitalizations, ER, or urgent care for medical intervention and no change in ch ronic 
prescription medications for at least 60 days. Changes in medications due to insurance or 
financial reasons and when within the same class of medications or changes for 
improvements in medical conditions are not exclusionary. Medications which are ta ken prn 
are also no exclusionary.  
4. Expressed interest and availability to fulfill the study requirements  
5. For females of child -bearing potential *, must a gree to acceptable birth control&, 4 weeks 
before enrollment and through 4 weeks after last vaccination.  
*  females of child -bearing potential are defined as: not sterilized via tubal ligation, bilateral 
oophorectomy, salpingectomy, hysterectomy, or successful Essure® placement (permanent, 
non-surgical, non -hormonal sterilization) with documented radiological  confirmation test at 
least 90 days after the procedure, and still menstruating or <1 year of the last menses if 
menopausal.  
&  acceptable birth control includes: non -male sexual relationships, abstinence from sexual 
intercourse with a male partner, monoga mous relationship with vasectomized partner who 
has been vasectomized for 180 days or more prior to the subject receiving the first study 
vaccination, barrier methods such as condoms or diaphragms with spermicide or foam, 
effective intrauterine devices, Nu vaRing®, and licensed hormonal methods such as implants, 
injectables, or oral contraceptives.  
6. Agrees not to participate in another clinical trial at any time during the study period.  
7. Agrees to allow for the indefinite storage of blood samples for future research use.  
3.2 Exclusion Criteria  
Subjects who meet any of the following criteria at baseline will be excluded from participating in 
the study:  
1. History of typhoid vaccination or known history of typhoid infection within 5 years  
2. Unacceptable laboratory abnormality from screening (prior to first vaccination) or upon 
safety laboratory testing ( prior to  second vaccination) as listed below.  Laboratories with 
abnormalities which are possibly transient in nature may be repeated  one time.  
a. Hemoglobin, white blood cell (WBC) count, absolute n eutrophil count  (ANC) , or 
platelet count of an unacceptable value, according to Appendix B  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 27 - b. Creatinine , AST, ALT, total bilirubin, or C -reactive protein of an unacceptable value, 
according to Appendix B   
c. Positive serology for hepatitis C or HIV antibody or hepatitis B surface antigen.  
(Subjects will be informed if their results are positive for hepatitis C, HIV antibody or hepatitis 
B surface antigen and will be referred to a primary care provider for follow up of these 
abnormal laboratory tests .) 
3. For women  of child -bearing potential , positive serum pregnancy test (during screening 
within 45 days of enroll ment) or positive urine pregnancy test ( prior to and within 24 
hours of administering each dose of vaccine).  
4. Nursing mother.  
5. Temperature > 38.0°C (100.4°F) or symptoms of an acute self -limited illness such as an 
upper respiratory infection , including of a COVID -19 infection#, or gastroenteritis within 
10 days prior to each dose of vaccine.  
# Symptoms of a COVID -19 infection include fever, chills, cough, shortness of breath or 
difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste o r smell, sore 
throat, congestion or runny nose, nausea or vomiting, and diarrhea.  
https://www.cdc.gov/coronavirus/2019 -ncov/symptoms -testing/symptoms.html   
6. Medical, oc cupational, or family problems as a result of alcohol or illicit drug use during 
the past 12 months.  
7. Diagnosis of schizophrenia or other major psychiatric disease  
8. Failure to pass Comprehension Assessment Tool  during screening (70% correct 
answers are required to pass . Subjects will be provided the opportunity to  repeat the test 
once ).  
9. Receipt of an experimental agent (vaccine, drug, device, etc.) within 28 days before 
enrollment or expects to receive an experi mental agent during the study period.  
10. Receipt of any licensed vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for 
live vaccines) before enrollment in this study.  
11. Known sensitivity to any ingredient in the study vaccine , including a history of  severe 
allergic reaction to tetanus  vaccine . 
12. Receipt of immunoglobulin or other blood product within the 3 months prior to 
vaccination in this study.  
13. Immunosuppression as a result of an underlying illness or treatment with 
immunosuppressive or cytotoxic d rugs, or use of anticancer chemotherapy or radiation 
therapy within the preceding 36 months.  
14. Long -term use (> 2 weeks) of oral or parenteral steroids (glucocorticoids), or high -dose 
inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent ) within 
the preceding 6 months (nasal and topical steroids are allowed).  
15. Other condition that in the opinion of the investigator would jeopardize the safety or 
rights of a volunteer participating in the trial or would render the subject unable to comply 
with the protocol.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 28 - 3.3 Enrollment and Randomization Procedures  
Per International Conference on Harmonisation  (ICH) guideline E6: Good Clinical Practice 
(GCP), screening records will be kept at the clinical site to document the reason why an 
individual was screened, but failed trial entry criteria. The reasons why individuals failed 
screening will be recorded in the data system.  
3.3.1  Re-screening procedure  
There may be situations in which a subject is not able to be randomized within 45 days of 
his/her  Screen ing Visit.  In these instances, the subject may need to be re -screened  including 
re-consent .  This will involve undergoing all screening procedures again.  
Study participants that meet all inclusion and exclusion criteria and have signed the informed 
consent form will be assigned a s ubject  identification number .  A randomization code will be 
prepar ed by a CVD statistician and will determine the blinded assignment of each subject to a 
treatment arm. A designated independent individual (e.g., Independent Safety Monitor) will be 
provided with a back -up randomization code list for emergency unblinding p urposes and which 
will be maintained in a secure location.  
Subjects, investigators, and study personnel performing any study -related assessments 
following study vaccine administration will be blinded to subject treatment assignment. 
Laboratory personnel pe rforming the immunogenicity assessments will also remain blinded to 
subject treatment assignment.  
3.4 Withdrawals and Discontinuation from Study  
Participation in the study is strictly voluntary.  Participants have the right to withdraw from the 
study at any ti me and for any reason, without penalty or prejudice to further treatment.  The 
Principal Investigator and/or designee may, at their own discretion, terminate a subject from 
continuing in the study if it is considered to be in the participant’s best welfare , or if the 
participant is not willing or able to comply with the study requirements.  The reason for 
withdrawal or termination will be documented.  Study participants may voluntarily withdraw their 
consent for participation at any time and for any reason, without penalty.  A study participant 
may be withdrawn from the study for the following reasons:  
• Medical illness or a new clinical  finding which in the opinion of the investigator could 
compromise the safety of the subject or interfere with the evaluation of the safety, 
tolerability, or immunogenicity of the study products . 
• The subject no longer meets eligibility criteria . 
• As deemed necessary by the investigator for non -compliance or other reasons.  
• Subject lost to follow -up. 
• Termination of the study.  
• New in formation becomes available that makes further participation unsafe.  
Handling of Participant Withdrawal or Termination . Every effort will be made to undertake 
protocol -specified safety follow -up procedures to capture AEs, serious adverse events (SAEs), 
and unanticipated problems (UPs). In the event of withdrawal or termination from the study, 
reasonable efforts should be made to conduct the following procedures:  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 29 - • Review diary card/ memory aid, if still in use prior to withdrawal  
• Updating any ongoing AE/SAEs that remain ongoing at time of subject’s last visit prior to 
withdrawal  
• Query about AEs, SAEs and concomitant medications if the interval between the 
subject’s last visit and the time of withdrawal is within the protocol defined reporting 
period  
• Targeted physical examination, if there are any ongoing AEs at the time of withdrawl  
• Blood for safety laboratory testing, if withdrawal occurs before the day 8 visit  
• Update contact information  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 30 - 4 INVESTIGATIONAL PRODUCTS  
4.1 Description of Investigational Products  
4.1.1  Trivalent, with preservative (multi -dose vials)  
This study product consists of a c GMP lot of a trivalent S. Enteritidis/ S. Typhimurium/ S. 
Typhi Vi conjugate vaccine consisting of a 1:1:1 mix of S. Enteritidis COPS  linked to 
Phase 1 Enteritidis flagellin (FliC) subunits and S. Typhimurium COPS  linked to Phase 1 
Typhimurium flagellin (FliC) subunits, plus Typbar TCV® (S. Typhi Vi capsular 
polysaccharide linked to tetanus toxoid protein).  The study product is presented in multi -
dose vials containing 2 -phenoxyethanol preservative.  
4.1.2  Placebo  
The placebo  consists of the buffer vehicle in which the conjugate vaccines are 
suspe nded, with 2-phenoxyethanol preservative.  
4.2 Formulation, Storage, Packaging, and Labeling  
4.2.1  Trivalent, with preservative (multi -dose vials)  
Each vial holds 2.5 mL (plus overfill) of  material for which a 0.5 mL volume contains  S. 
Enteritidis 25 µg (by polysacch aride weight) , S. Typhimurium 25 µg (by polysaccharide 
weight) , and S. Typhi Vi 25 µg (by polysaccharide weight) conjugate  vaccine , plus 
Tween -80 and PBS , and 2 -phenoxyethanol preservative . Each multi-dose vial is to be 
stored between 2 -8°C, not to be froz en. 
4.2.2  Placebo  
Each vial  holds 2.5 mL (plus overfill) of  material for which a 0.5 mL volume contains 
PBS, Tween -80, plus 2 -phenoxyethanol preservative. Each multi-dose vial of placebo is 
to be stored between 2 -8°C, not to be frozen.  
4.3 Preparation and Administra tion 
Step 1 ( Cohort A ). For each dose of vaccine, a 0.25 mL volume from a vial contain ing study 
product is to be mix ed with 0.75 mL of placebo (PBS, Tween -80, and 2 -phenoxyethanol) .  After 
mixing , 0.5 mL should be withdrawn into a 1 mL syringe  -- this volume should contain ~6.25 µg 
of product (by polysaccharide weight) as a dose in 0.5 mL . The 0.5 mL of placebo will contain 
only buffer and preservative . 
Step 2 ( Cohort B ) and Cohort C .  For each do se of vaccine, a 0. 5 mL volume from a vial 
containing study product is to be mixed with  0.5 mL of placebo (PBS, Tween -80, and 2 -
phenoxyethanol) .  After mixing , 0.5 mL should be withdrawn into a 1 mL syringe -- this volume 
should be equivalent to ~12.5 µg of test product (by polysaccharide weight) dose  in 0.5 mL . The 
0.5 mL of placebo will contain only buffer and preservative.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 31 - Step 3 ( Cohort C ). For each dose of vaccine, a 0.5 mL volume from a vial containing study 
product is to be directly withdrawn into a 1  mL syringe -- this should be equivalent to ~25 µg (by 
polysaccharide weight) dose  in a volume of 0.5 mL. The 0.5 mL of placebo will contain only 
buffer and preservative.  
The diluted study product vial can be used up to 4 hours, if stored at 2 -8 °C, or up to a 
maximum of 30 minutes if kept at room temperature.  Prepared diluted vaccine must be 
manually shaken gently before using. Once the mixed vaccine has been drawn into a syringe, it 
should be administered within 30 minutes.  Any unused vaccine or waste m aterial should be 
disposed of in accordance with local requirements.  
Each vial (holding 2.5 mL of material plus overfill) shall only be used to withdraw a maximum of 
5 doses (5 punctures per vial) for each day of scheduled administration. Each multidose vi al will 
only be used for one day . At the end of each vaccination  day, unused vaccine in the multidose 
vial will be marked as un -usable. The Pharmacy will be responsible for keeping track of the 
number of doses drawn per vial and maintaining proper investig ational product accountability on 
the accountability log.  
4.4 Study Product Accountability  
The study product will be stored in and dispensed by the University of Maryland Medical Center 
(UMMC) Investigational Drug Service (IDS) pharmacy  or Pharmaron . The FDA requires 
accounting for the disposition of all investigational products. The Investigator is responsible for 
ensuring that an accurate record of product disposition is maintained and product is dispensed 
only by authorized personnel as required by applicab le regulations and guidelines. Records of 
product disposition as required by federal law consist of the date received, date administered, 
quantity administered, and the subject number to whom the study product was administered. 
The investigational pharmaci st will be responsible for maintaining accurate records of the 
shipment and accountability of the study product.  
For participants enrolled at CVD, t he preparation and dispensing of the study product is 
performed by the IDS Pharmacy and the dosing of subjects is performed by CVD research staff; 
the process and procedures are documented and maintained in a secure location that is 
segregated from the bli nded research staff. Participants enrolled at Pharmaron will have the 
study product preparation and administration according to their internal standards.  The 
pharmacy records (IDS pharmacy , CVD , and Pharmaron ) will be made available for inspection 
by exte rnal monitors and by the relevant regulatory agencies (e.g., FDA) at any time.  
4.5 Masking of the Study Product  
A prospectively assigned vaccinator and checker will be designated as unblinded personnel and 
will not have any role in the assessment of adverse ev ents in study participants.  Unblinded 
personnel will be responsible for the preparation of the study products and for the blinded 
labeling of the study products. The unblinded staff will be responsible for maintaining the 
randomization key and will secure  these study documents in a locked cabinet.  
The PI or the Data and Safety Monitoring Board must submit a written request, to inform each 
other, for emergency unblinding, if this were to be performed. The written request must clearly 
state the justification  for the emergency unblinding and describe which specific participants are 
to be unblinded. This document will be filed in the study regulatory file.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 32 - 5 STUDY PROCEDURES  
5.1 Clinical Evaluations  
Medical History: Will be obtained by interview of the participants. Participants will be queried 
regarding a history of significant medical disorders of the head, eyes, ears, nose, throat 
(HEENT), mouth, cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, 
urologic, nervous system, blood, lymph gl ands, endocrine system, musculoskeletal system, 
skin, and genital/reproductive tract. A history of any allergies, cancer, immunodeficiency, 
psychiatric illness, substance abuse, and autoimmune disease will be solicited.  
Medication History: All current medi cations and medications taken in the 28 days prior to 
enrollment (prescription and over -the-counter drugs will be included as well as vitamins and 
supplements) through 28 days after the last vaccination or early termination (if prior to 28 days 
from last v accination ), whichever occurs first. Assessment of eligibility also will include a review 
of permitted and prohibited medications (per the exclusion criteria).  
Physical Examination: At screening appropriate study personnel will record oral temperature, 
pulse and blood pressure and perform a focused physical examination to assess general 
wellness which will include the following areas/systems:  HEENT; lymph nodes; skin; 
pulmonary; cardiovascular; abdominal; neurological; and musculoskeletal systems. The phy sical 
examination should specifically address issues identified by the medical history of the 
participant. At following visits including enrollment, oral temperature, pulse, and blood pressure 
will be recorded and a targeted physical examination may be con ducted if indicated based on 
review of medical history.  
Reactogenicity Assessments: Will include brief history for assessment of AE/SAEs just prior to 
and foll owing vaccination (Day  1 for Cohorts A -B and Days 1 and  29 for Cohort s C and  D), 
which includes an assessment of systemic and local reactions.  Participants will be observed in -
clinic for 20 minutes following each vaccination.  
Memory Aids: All participants will complete a subject memory aid distributed after each 
vaccination. Subject memory aids will  be reviewed with the participant for AE/SAEs during visits 
occurring 7 days after each dose of vaccine . Following review, the appropriate case report form 
(CRF) will be completed by the study staff. Memory aids will not be retained as a source 
document.  
5.2 Clinical Laboratory Evaluations  
A total of 16 mL blood will be collected for screening clinical labs for the evaluation of eligibility.  
If screening laboratory results are out of range value, they may be repeated once provided there 
is an alternative expla nation for the out of range value. Participants must have acceptable 
screening laboratory findings prior to enrollment.  The acceptable ranges for study eligibility are 
listed in Appendix B . 
For the assessment of safety, a total of 12.5 mL of blood will be collected for clinical safety labs 
on Day 1 (pre -vaccination) and the Day 8 (7 -days post dose #1) visit. Th is evaluation is to 
include a CBC with differential for total white blood cells ( WBC) count , hemoglobin ( Hg), 
absolute neutrophil count ( ANC ), platelet count, creatinine, aspartate aminotransferase  (AST), 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 33 - alanine a minotransferase (ALT), total bilirubin  (TBIL) , and C -reactive protein  (CRP) .  On Day 2 
(one day after receipt of the first do se of vaccine ), a 3.5 mL volume of blood will be collected for 
the assessment of C -reactive protein only. The grading of toxicity for the clinical safety lab 
values that are not in the normal range is provided in Appendix C . 
Due to the U.S. Public Health E mergency with COVID -19, SARS -CoV-2 testing will be 
performed on the days of scheduled vaccination. These test results are not intended to inform 
the eligibility of participants for vaccination , as the results are likely to be available after 2 -3 
days. Howe ver, for possible pre -symptomatic participants (i.e., eligible due to the absence of 
symptoms at the time of vaccination) the positive test result could be used to provide an 
alternate etiology for the development of symptoms due to COVID -19 rather than du e to the 
study product.   The test results of acute infection (positive PCR) or prior infection (positive 
antibody) will also be used in planned stratified analysis of the immunology outcomes, as 
COVID -19 infection may alter the immune response to vaccinati on. The results of SARS -CoV-2 
testing will be provided to participants at their Day 7 and Day 36 visits. If SARS -CoV-2 testing 
results are received prior to th ese visits , the research team may call participants to report these 
results . 
All women of child -bearing potential will have a serum  pregnancy test performed during 
screening and a urine pregnancy test on the vaccination days. The results of the urine 
pregnancy test must be negative prior to enrollment in the study, and prior to each vaccination.  
When a result is abnormal and satisfies the toxicity grading scale, the result must be recorded 
as a laboratory  AE and followed until resolution or it becomes stable . If a laboratory value is 
abnormal but does not satisfy the toxicity grading scale, then the abnormality must be assessed 
by the site PI or designee for clinical significance . For all  clinically significant  abnormalities or 
grade 1 or higher abnormalities , the value should be recorded as a laboratory AE . Any grade 2 
or higher abnormality must be  followed until resolution , it becomes stable , or it becomes grade 1 
or lower .  
5.3 Research Laboratory Assays  
Blood volumes have been summarized in Appendix A  (Schedule of Events) .  The Immunological 
Assays to be performed with these blood specimens have been d escribed in Section 8 
(Assessment of Immunogenicity) . 
The collection of oral crevicular fluid will be performed with a porous foam swab device that is 
gently rubbed along the gumline until the foam sponge is saturated. The foam swab is then 
inserted into an extraction tube that is prefilled with a buffer solution that elutes the antibodies 
from the foam swab. A dropper tip, attached to the tube and swab, effectively acts as a syringe -
like device whic h simultaneously squeezes the oral fluid -buffer liquid out of the foam and into 
the collection tube. Antibodies in oral fluid will be measured by the method described in Section 
8. 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 34 - 6 STUDY SCHEDULE   
6.1 Screening Visit (Day -45 till -2) 
After a participant has s igned informed consent and has successfully completed the 
Comprehension Assessment Tool , the following will be performed:  
• Assignment of study subject identification number  
• Complete medical history will be obtained by interview  
• Record all concomitant medica tions taken within 28 days prior to signing the informed 
consent form  
• Measure oral temperature, blood pressure, and pulse.  
• Collect height and weight  
• A targeted physical examination is to be performed by a licensed study clinician  
• A blood volume of 16 mL is to be obtained for screening laboratories, consisting of:  
o Hematology  (4 mL, lavender, EDTA tube) : total WBC, ANC, Hg, platelets  
o Chemistries  (8.5 mL, red, serum separator tube) : creatinine, AST, ALT , TBIL, 
and CRP  
o Serologies  (from same 8. 5 mL  SST tube for chemistries ): hepatitis B surface 
antigen (HBsAg)  and hepatitis C virus (HCV) antibody  
o Human immunodefienciency virus (HIV) antibody  (3.5 mL, serum separator tube)  
o For women of child -bearing potential: serum β-HCG  (to be analyzed from the 
specimen obtained for chemistries)  
6.2 Visit 1 - Enrollment & Vaccination Dose #1 (Day 1)  
A participant that satisfies eligibility will be given an appointment for enrollment. The following 
activities will be completed prior to vaccination:  
• interim  medical histor y or concomitant medications  
• A targeted physical examination, if indicated based on review of interim medical history  
• Measure oral tempera ture, blood pressure, and pulse  
• Final review of all inclusion and exclusion criteria  
• A blood volume of 15 mL for the collection of serum, 80 mL for the collection of 
peripheral blood mononuclear cells (PBMC), and 12.5 mL for safety laboratory 
assessment, consisting of:  
o Hematology (4 mL, lavender, EDTA tube): total WBC, ANC, Hg, platelets  
o Chemistries (8.5 mL, red, serum separator tube): creatinine, AST, ALT, TBIL, 
CRP  
o SARS -CoV-2 antibody test  (5 mL) , to be performed at University of Maryland 
Pathology Associates (UMPA)  
• Collect nasopharyngeal swab for SARS -CoV-2 PCR test, to be performed at U niversity 
of Maryland Pathology Associates (UMPA)  
• For women of child -bearing potential, a urine pregnancy will be performed  
• Collect oral fluid (crevicular fluid)  
• Confirmation of ongoing informed consent  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 35 - Enrollment and randomization may be performed after e ligibility has been confirmed.  Once 
randomization has been completed, a prospectively assigned unblinded vaccinator and 
unblinded checker will check the  randomization treatment assignment and prepare the masked 
study product.   The injection site will be c leaned with an alcohol swab. The assigned study 
product will be administered to the deltoid muscle by intramuscular route. The study product 
administered , the location, and time of administration will be documented on the appropriate 
source document.  
Following receipt of dose #1 of study product, the participant will be directly observed for at least 
20 minutes.  The PI (or designee) may determine that a participant requires longer on -site 
observation or clinical assessment, as needed  for sig nificant adverse events .  Prior to 
discharge, the participant will be provided with training on the completion of a Memory Aid , 
given a digital thermometer, and provided follow -up visit information and contact phone 
numbers for study staff.  
6.3 Visit 2 Follow Up (Day 2)  
The participant will return to clinic to complete the following:  
• Review of the Memory Aid  and retraining on the use of the Memory Aid , if necessary  
• Any other unsolicited adverse events (AEs) will be recorded  
• A blood volume of 3.5 mL for safety l aboratory assessment of CRP  
• Prior to discharge, a reminder of the date and time for the next visit  will be given to the 
participant  
6.4 Visit 3 Follow Up (Day 8 ±1) 
The participant will return to clinic to complete the following:  
• Interim medical history or concomitant medications  
• A targeted physical examination, if indicated based on review of interim medical history  
• Collection and review of the Memory Aid  for reactogenicity information and completion of 
the corresponding source document.  
• Any oth er unsolicited adverse events (AEs) will be recorded  
• A blood volume 12.5 mL for safety laboratory assessment, consisting of : 
o Hematology (4 mL, lavender, EDTA tube): total  WBC, ANC, Hg, platelets  
o Chemistries ( 8.5 mL, red, serum separator tube): creatinine, AST, ALT , TBIL, 
CRP  
• A blood volume of 40 mL for PBMC (for Cohort s B, C, and  D only)  
• If available, t he result from the PCR testing performed on Day 1 will be provided to the 
participant  
• Prior to discharge, a reminder of the date and time for the next visit will be given to the 
participant  
6.5 Visit 4 Follow Up (for Cohorts A -B) or Vaccination Dose #2 
(for Cohort s C and  D) (Day 29 ±3) 
The participant will return to clinic to complete the following , prior to vaccination : 
• Interim medical history or concomitant medications  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 36 - • A targeted physical examination, if indicated based on review of interim medical history  
• Collection of any AEs will be recorded  
• A blood volume of 20 mL for serum and 80 mL for PBMC  
o 5 mL for a SARS -CoV-2 antibody test, to be performe d at University of Maryland 
Pathology Associates (UMPA)  
• Collect nasopharyngeal swab for SARS -CoV-2 PCR test, to be performed at University 
of Maryland Pathology Associates (UMPA)  
• Collect oral fluid (crevicular fluid)  
• For women of child -bearing potential, a urine pregnancy will be performed  (for Cohort C 
and D only)  
• Confirmation of eligibility for dose #2 , if Cohort C and D 
For Cohort C and D, the unblinded vaccinator and unblinded checker will administer the 
appropriate study product and record the procedure on the respective source document.  
Following receipt of vaccine, the participant will be directly observed for at least 20 minutes and 
given instructions on the completion of a Memory Aid .  Prior to discharge, follow -up visit 
information and  contact numbers will be provided.  
6.6 Visit 5 Follow Up , only for Cohort C and D (Day 36 ±1) 
The participant will return to clinic to complete the following:  
• Interim medical history or concomitant medications  
• A targeted physical examination, if indicated base d on review of interim medical history  
• Collection and review of the Memory Aid  for reactogenicity information and completion of 
the corresponding source document.  
• Any other unsolicited AEs will be recorded  
• A blood volume of 40 mL for PBMC  
• The result from the PCR testing performed on Vaccination Dose #2 (Day 29) will be 
provided to the participant  
• Prior to discharge, a reminder of the da te and time for the next visit will be given to the 
participant  
6.7 Follow Up , Visit 5 for Cohort A -C, Visit 6 for Cohort C and D 
(Day 57 ±3) 
The participant will return to clinic to complete the following:  
• Interim medical history or concomitant medications  
• A targeted physical examination, if indicated based on review of interim me dical history  
• Collection of any AEs (for Cohort C and D only) or SAEs will be recorded  
• A blood volume of 15 mL for serum and 80 mL for PBMC  
• Collect oral fluid (crevicular fluid)  
6.8 Final Follow Up , Visit  6 for Cohort A -B (Day 180 ±14), Visit 7 
for Cohort C an d D (Day 210 ±14) 
The participant will return to clinic to complete the following:  
• Interim medical history  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 37 - • A targeted physical examination, if indicated based on review of interim medical history  
• Collection of SAEs  will be recorded  
• A blood volume of 15 mL for serum and up to 80 mL for PBMC  
• Collect oral fluid (crevicular fluid)  
6.9 Unscheduled Visits  
Unscheduled visits may be performed at the participant’s request or by judgement of the PI (or 
designee) when necessary for the diagnosis an d/or management of a finding or AEs.  All 
unscheduled visits are to be documented.  
6.10 Early Termination  
A participant may withdraw from the study for any reason or the PI (or designee) may withdraw 
the subject for the welfare of the participant.  At this visit , vital signs (oral temp, BP, and pulse) 
and AE recording will be completed.   
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 38 - 7 ASSESSMENT OF SAFETY  
7.1 Specification of Safety Parameters  
Safety will be assess ed by the frequency and severity of:  
1. Solicited adverse events, reactogenicity events occurring from the time of each 
vaccination through  7 days after vaccination, to include:  
a. Local injection site reactions: pain, erythema (redness), induration (swelling), and 
ecchymosis (bruising) . 
b. Systemic reactions: fever, chills, fatigue (tiredness), ma laise (general unwell 
feeling), myalgia (body aches), (arthralgia (joint aches), nausea, and headache.  
2. Study product -related unsolicited adverse events, non -serious adverse events occurring 
from the time of each vaccination through 28 days after vaccinatio n. 
3. Study product -related serious adverse events occurring from the time of the first 
vaccination and through the final visit (or time of early withdrawal, when applicable) for 
each participant.  
4. New-onset chronic medical conditions occurring from the time o f the first vaccination and 
through the final visit (or time of early withdrawal, when applicable) for each participant.  
 
Safety assessment will also include l aboratory parameter s which will be evaluated at baseline 
(pre-vaccination) and 7 days after the first dose of vaccine and  are also to include : WBC, ANC, 
Hg, platelet count s, creatinine, AST, ALT, TBIL, and C RP. CRP will also be evaluated at one 
day after receiving the first dose of vaccine (Day 2).   
7.2 Methods and Timing for Assessing, Recording, and 
Analyzing Safety Parameters  
Adverse Event  (AE):  ICH E6 defines an AE as any untoward medical occurrence in a patient 
or clinical investigation subject administered a pharmaceutical product regardless of its ca usal 
relationship to the study treatment. An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated with 
the use of medicinal (investigational) product. The occurrence o f an AE may come to the 
attention of study personnel during study visits and interviews of a study recipient presenting for 
medical care, or upon review by a study monitor.  
All AEs including local and systemic reactions not meeting the criteria for “serio us adverse 
events” should be captured on the appropriate CRF. Information to be collected includes event 
description, time of onset, clinician’s assessment of severity, relationship to study product 
(assessed only by those with the training and authority t o make a diagnosis, which would 
include MD, PA, and Nurse Practitioner, listed on the FDA Form 1572), and time of 
resolution/stabilization of the event. All AEs occurring while on study must be documented 
appropriately regardless of relationship. All AEs w ill be followed to adequate resolution.  
Any medical condition that is present at the time that the patient is screened should be 
considered as baseline and not reported as an AE. However, if it deteriorates at any time during 
the study, it should be recor ded as an AE.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 39 - Special Circumstance of COVID -19 Pandemic . While there is a U.S. Public Health 
Emergency for COVID -19, there is the risk of community transmission of infections. The testing 
of both anti -SARS -CoV-2 antibody and presence of virus by PCR on the  days of vaccination 
(both dose #1 and #2) are intended to provide the investigators with information on potential 
asymptomatic or presymptomatic infections at vaccination, but the results will not be available in 
time prior to vaccination.  Therefore, the  results are intended to potentially provide alternate 
etiology for reactogenicity that might be observed post -vaccination which could be due to a 
COVID -19 infection rather than to the study product.  The results of SARS -CoV-2 testing will be 
provided to pa rticipants at their Day 7 and Day 36 visits. If SARS -CoV-2 testing results are 
received prior to the se visits , the research team may call participants to report these results.  
Severity of Event : All AEs will be assessed by the clinician using a protocol de fined grading 
system. For events not included in the protocol defined grading system, than the following 
guidelines will be used to quantify intensity.  
• Mild – Grade 1: events require minimal or no treatment and do not interfere with the 
patient’s daily ac tivities.  
• Moderate – Grade 2: events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with functioning.  
• Severe – Grade 3: events interrupt a patient’s usual daily activity and may require 
systemic drug therapy or other treatment. Severe events are usually incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events  characterized as 
intermittent require documentation of onset and duration of each episode.  
Relationship to Study Product :  The clinician’s assessment of an AE's relationship to Vaccine 
is part of the documentation process, but it is not a factor in determ ining what is or is not 
reported in the study. If there is any doubt as to whether a clinical observation is an AE, the 
event should be reported. All AEs must have their relationship to study product assessed using 
the terms: related or not related. In a c linical trial, the study product must always be suspect. To 
help assess, the following guidelines are used.  
• Related – The event is temporally related to the administration of the study product and 
no other etiology explains the event.  
• Not Related – The eve nt is temporally independent of study product and/or the event 
appears to be explained by another etiology.  
Serious Adverse Event (SAE) : An adverse event or suspected adverse reaction is considered 
“serious” if, in the view of either the investigator or sp onsor, it results in any of the following 
outcomes:  
• Death,  
• a life -threatening adverse event*,  
• inpatient hospitalization or prolongation of existing hospitalization,  
• a persistent or significant incapacity or substantial disruption of the ability to condu ct 
normal life functions, or  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 40 - • a congenital anomaly/birth defect.   
• Important medical events that may not result in death, be life -threatening, or require 
hospitalizations may be considered serious when, based upon appropriate medical 
judgment they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room o r at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse.  
* Life-threatening adverse event . An adverse event is considered “life -threatening” if, in the view 
of either the investigator or sponsor, its occurrence places the patient or subject at immediate 
risk of death.  It does not include an adverse event, had it occurred in a more severe form, might 
have caused death.  
All SAEs will be : 
• recorded on the appropriat e SAE Form  
• followed through resolution by a study physician  
• reviewed and evaluated for intensity and causality by a physician listed on the Form FDA 
1572 as the Principal Investigator or Sub -Investigator.  
• reviewed by the Independent Safety Monitoring Commi ttee and  the IRB.  
7.3 Halting Rules  
If any of the following halting rules are met, the study will not proceed with the remaining 
enrollment or dose escalation without a review by and recommendation from an Independent 
Safety Monitoring Committee:  
• Two or more s ubjects in a dosage cohort experiences the same systemic toxicity, except 
for fever, of grade 3 or above and judged to be associated with vaccine.  
• Two or more subjects in a dosage cohort experiences a fever at or greater than grade 3 
within 7 days of vacci nation.  
• Two or more subjects in a dosage cohort experiences the same grade 2 or greater 
abnormal laboratory value and judged to be associated with vaccine.  
• Three or more subjects in a dosage cohort experience the same localized toxicity  (local 
pain or ind uration)  at grade 3 or above judged to be associated with vaccine.  
• Any death occurring within 7 days following administration of vaccine that was not the 
result of trauma or accident.  
• Any subject experiences an SAE determined to be related to vaccine.  
The study may also be halted due to PI or Sponsor discretion.  
7.4 Safety Oversight  
Safety oversight will be under the direction an Independent Safety Monitoring Committee 
(SMC). There will be an Independent Safety Monitor (ISM) who will be independent of the study  
team, local to the study site and will be provided access to study records, if required. The SMC 
will be comprised of the ISM plus at least two independent members with expertise in infectious 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 41 - diseases and/or clinical trials who will advise the Sponsor an d the PI. SMC quorum is defined as 
a simple majority. The SMC will be responsible for three scheduled meetings to review the 
available data up to 7 -days post -first dose of vaccination for each Cohort ; for Cohorts A -C, the 
SMC will determine whether the tri al may proceed to the next dosage cohort.  The ISM will 
review all SAEs in real time and provide a written ISM assessment regarding the event.  The 
SMC may receive a final study report, but a recommendation will not be necessary.  
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 42 - 8 ASSESSMENT OF IMMUNOGENICITY  
8.1 Enzyme -linked Immunosorb ent Antibody Assay (ELISA)  
The serum IgG levels against the respective antigens  will be measured, as previously 
described.15,17,18  Briefly, 96 -well plates are coated with the respective COPS, Vi, or FliC antigen 
(5 µg/mL) . After overnight incubation, plates are washed and sera are teste d in serial dilutions. 
Specific antibodies w ill be detected using peroxidase -labeled anti -human  IgG and 3,3,5,5 -
Tetramethylbenzidine (TMB) substrate. Test and control sera are run in duplicate. Titers are 
calculated by interpolation of absorbance values of  test samples into the linear regression curve 
of a calibrated control (reference serum). The endpoint titers will be reported as ELISA units 
(EU), which  represent the inverse of the serum dilution that produces an absorbance value of 
0.2 above the blank. Seroconversion will be  defined as a 4 -fold increase in the antibody titer 
after immunization.  
8.2 Opsonophagocyt ic Activity  (OPA)  assay  
The OPA assay is to be performed as previously described38,39 with some m odifications to the 
originally described Lindow  et al. method.40  Heat-inactivated serum samples will be added to 
bacteria and i ncubated for 30 min at 37°C to allow for antibody binding (opsonization).   THP-1 
macrophage monolayers  will be incubated with opsonized bacteria in antibiotic -free medium for 
30 min. (OPA) and 24 hr (survival analysis).  Following incubation, extracellular  bacteria will be 
killed (using gentamicin ) and f or the opsonophagocytosis assays, macrophages will lysed  and 
the lysate will be plated onto LB plates, for enumeration of the colony forming units ( CFU). For 
the survival assays, plates will be incubated ove rnight and t he surviving bacteria will be counted 
by lysing and plating the cell lysates onto LB plates as described above.  
8.3 Serum Ba ctericidal Activity (SBA) assay  
The SBA assay is planned to be performed as previously described.41 Bacteria, from l og-phase 
cultures , are added  to a plate for incubation with guinea pig complement and/or baby rabbit 
complement . Serially diluted heat -inactivated serum samples will be added to the  plate. The 
SBA antibody titer will be defined as the reciprocal of the highest serum dilution that 
produces>50% killing in relation to the killing observed for the control wells containing bacteria 
and complement only (i.e., no serum). The titers will be deter mined from the mean bacterial 
count from triplicate wells.  
8.4 Antibody Secreting Cells (ASC) assay  
Plasmablasts secreting antibodies that recognize the respective COPS, Vi, FliC, or TT antigen  
will be measured using ELISPOT , using previously described methods .42 The frequency of spot -
forming cells (SFC) from replicate wells will be determined and reported as ASC/106 PBMC. A 
positive response will be defined as ≥8 ASC/106 PBMC . Antibodies in lymphocyte supernatants 
(ALS) from these plasmablasts may also be collected and tested using the ELISA assay. From 
some PBMCs there may be the measurement of the mucosal homing potential of plasmablasts . 
PBMC will be enumerated by flow cytometry based on molecules expressed in naïve (B n; 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 43 - CD19+ IgD+ CD27 -) and memory B (B M; CD19+ IgD - CD27+) cells which direct them to home 
to distinct sites (e.g., integrin α4β7, CD62L, CXCR3).  
8.5 Circulating B cell memory cells (BM) and Cell -mediated 
Immunity (CMI) (cytokines, T cell effector and memory 
(including circulating T follicular/helper cells -cTfh-), T cell 
homing  
Blood will be drawn before each vaccination (Days 1, 29, and 57) and on Days 85 and 209  
post-vaccination and isolated PBMC cryopreserved for studies of specific BM43-45 and CMI46-50 
responses, including cytokine production (e.g., interferon -γ) and expression of homing 
molecules in effector and memory T cells which might direct them to either mucosal or systemic 
effector sites.   Antigen specific cytokine -production a nd induction of effector and memory T 
cells, as well as cT fh, will be measured in cryopreserved PBMC stimulated with the appropriate 
antigens (e.g., FliC, tetanus toxoid).  Antigen -stimulated PBMC will be stained for conventional 
flow cytometry (using fluo rochrome -conjugated monoclonal antibodies) or mass cytometry 
(using metal -conjugated monoclonal antibodies), run in the corresponding instruments, and the 
data analyzed using supervised and non -supervised flow cytometry analytical packages.  The 
frequency of BM specific for COPS, Vi, FliC, and tetanus toxoid antigens will be measured by a 
previously described ELISPOT -based assay.   
8.6 Antibodies in Oral Fluid  
As opposed to IgA -rich saliva, oral crevicular fluid (the fluid found in the crevicle between the 
tooth and the gum) is a transudate of serum that is ~1% of the IgG concentration of the blood. 
Using the same method of measure serum ELISA antibody, the antibodies in oral fluid will be 
measured against Vi polysaccharide, TT, FliC, and COPS.  (reference: Tapia  MD, asetti MF, 
Cuberos, L, et al. Pediatr Infect Dis J  Sept 2006; 25(9): 819 -825) 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 44 - 9 QUALITY AND  MONITORING  
9.1 Quality Control and Quality Assurance  
All clinical trials conducted by the University of Maryland Center for Vaccine Development (CVD) 
are internally audited for quality assurance (QA) quality control (QC) under the CVD -Wide Quality 
Management Plan (QMP).  The purpose of the QMP is to describe  QA/QC procedures designed 
to ensure site and investigator compliance with applicable regulations, adherence to the IRB -
approved protocol, generation of credible, quality data, protect data integrity, and safeguard the 
safety and well -being of study partic ipants. The plan has the authority to enforce and correct 
clinical and laboratory deficiencies observed during the conduct of a trial/research study.   
Quality Management (QM) activities will proceed in compliance with E6(R2) Good Clinical 
Practice:  Integ rated Addendum to ICH E6(R1), March, 2018.  Consistent with the University of 
Maryland Center for Vaccine Development site -wide QMP, a Protocol -specific Quality 
Management Plan (QMP) (Appendix B  of the site -wide QMP ) of the will be developed for this 
proto col.  The Protocol -specific plan applies a risk -based approach to Quality Management (QM) 
focused on the essential elements of clinical trial conduct, i.e., recruitment strategies, the informed 
consent process, eligibility, study -related procedures, clinic al and safety assessments, 
AEs/SAEs, study product management, specimen management, and data management.  The 
plan will also outline site delegation of QC/QA responsibilities, frequency of regulatory file reviews, 
the audit schedule (e.g., sample size, aud it frequency, critical data that will be reviewed, 
communication, etc.), documentation and reporting of QA findings /queries , and the development 
of corrective action preventive action (CAPA) plans (as indicated).  
Pharmaron will implement a site -specific QM P, similar to the CVD’s QMP and following the CVD’s 
standards.  
9.2 Clinical Monitoring  
Site monitoring is conducted to ensure that the rights and well -being of human subjects are 
protected, that the reported trial data are accurate, complete, and verifiable, a nd that the conduct 
of the trial is in compliance with the currently IRB-approved protocol/amendment(s), with GCP, 
and with applicable regulatory requirement(s). Monitoring refers to the methods used by sponsors 
of investigational studies, or Contract Rese arch Organizations (CROs) delegated site monitoring 
responsibilities, to oversee the conduct of, and reporting of data from, clinical investigations. Site 
monitoring includes ensuring appropriate clinical investigator supervision of study site staff and 
third party contractors.  
In order to ensure protocol compliance, monitoring visits by a sponsor -designated professional 
or monitor will occur at scheduled intervals. The visit frequency will be defined in a monitoring 
plan (refer to Section 8.1 below) and communicated before study start to the principal 
investigator and all other appropriate study personnel . 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 45 - 9.3 Site Monitoring Plan  
Independent site monitoring will be conducted to assess the progress of the clinical trial and 
ensure that the rights, safety, and  well-being of study participants are protected, study 
procedures, laboratory procedures, study intervention administration, and data collection 
processes are of high quality that comply with ICH/GCP, federal, state, and local regulatory 
authorities and th at the study is conducted in accordance with the IRB -protocol and sponsor 
standard operating procedures (SOPs). Clinical monitoring of this protocol will be performed by 
qualified individuals selected by the sponsor in accordance with ICH/GCP (Section 5.18 .2) and 
as detailed in the monitoring plan.   
Site visits will be made at standard intervals as defined by the sponsor. Monitoring visits will 
performed in accordance with ICH/GCP (Section 5.18) and will include, but are not limited to, 
review of regulator y files, participant study charts inclusive of DCFs and source documents 
contained therein, informed consent forms, study product accountability records, medical and 
laboratory reports, etc. Study monitors will meet with investigators to discuss visit find ings, any 
problems and/or issues and actions to be taken, if any. The principal investigator will be 
responsible for review, follow -up and resolution of monitoring findings  
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 46 - 10 STATISTICAL CONSIDERATIONS  
10.1 Study Hypothesis  and Sample Size Considerations  
The ov erarching  hypothes is of this phase 1 study is t hat the trivalent S. Enteritidis/ S. 
Typhimurium/ S. Typhi Vi conjugate vaccine will be well -tolerated at all three dosage levels 
tested and that the highest dosage level will elicit the strongest serum anti-COPS, anti -FliC and 
anti-Vi antibody responses in humans.  The primary hypothesis of safety will be fulfilled if no 
participants develop a vaccine related SAE and each vaccine is well -tolerated.  The secondary 
hypothesis of immunogenicity will be fulf illed if each vaccine elicits an immune response by 
ELISA.   
The trial sample size is intended to minimize the number of subjects exposed to each vaccine 
until sufficient safety data have accumulated to proceed to larger trials. The phase 1 trial sample 
size was not derived to achieve a pre -specified statistical power. Instead, the sample size was 
selected to descriptively evaluate the safety and immunogenicity of these vaccines in a first -in-
man trial. As a result, there will be sufficient power to detect only very large differences in 
immunological responses among groups, and confidence limits will be fairly wide.   
The endpoint measures for the primary, secondary and exploratory objectives are listed in 
Sections 6.1, 6.2 and 6.3.  
10.1.1  Sample size  in Part 2 of the study  
The adaptive design for the Part 2 portion of this study will involve the evaluation of single dose 
vs. two -dose regimen s of the trivalent vaccine , in comparison to placebo . There is a  theoretical 
possibility of immunological “interference” with the addition of antigens in multivalent 
glycoconjugate vaccines .51 Under such circumstances, the responses to some antigens may be 
reduced. There is no  expect ation for  there to be differences in the seroconversion rates 
between single  dose and two -dose regimen s of glycoconjugate vaccines in healthy U.S. 
adults.52  On the other hand, the design  of Part 2 of the  study will substantiate moving forward 
with two-dose regimens  in sub -Saharan Africa where we do expect that more than a single d ose 
will be required in the target pediatric population53,54—so th e purpose is the demonstrat ion of  
safety with two sequential  doses and not for showing differences in immune responses.   
10.2 General Statistical Principles  
Descriptive Statistics . To summarize safety, the number and percentage of participants in each 
cohort that experiences each AE, categorized by body system and preferred term, will be 
tabulated with by vaccine received along with a corresponding two -sided exact 95% confidence 
interval (95%CI). For seroresponse rate endpoints, two -sided 95%CI for each proportion will be 
calculated.  When determining GMT antibody titer, the log values will be used to construct the 
95%CI using the t -distribution for the mean difference between three p air-wise vaccine groups. 
The mean difference and the corresponding CI limits will then be exponentiated to obtain the 
GMT ratio and corresponding CI.  If the values deviate from a log normal distribution, then a 
non-parametric method may be used for the an alysis of GMT.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 47 - Continuous Measures of Immune Response .  Continuous variables of interest that are not 
normally distributed will be transformed if needed . To compare each vaccine dose group with 
the placebo group, t test or Mann -Whitney U test will be used for continuous variables as 
appropriate    
Multiple Comparisons .  No formal statistical adjustment for multiple comparisons is planned. 
The investigators recognize that the study involves multiple comparisons (among vaccine 
doses, between vaccines, etc.) of  safety and immunogenicity parameters, and that statistically 
significant results could be obtained in some cases when there is no difference between the 
groups being compared. However, such instances (type I errors) should be infrequent; e.g., if 
we use p  <0.05 as the criterion for statistical significance, only 5% of all comparisons that are 
actually equivalent will be significant. Moreover, it is difficult to know exactly which comparisons 
should be included in an adjustment. (We would not want to includ e safety assessments, 
because the error of assessing a safe vaccine as unsafe is preferable to thinking that a truly 
unsafe vaccine is safe.) The main purpose of this trial is to provide data for making decisions 
about further study of this vaccine, and st atistical significance per se is not the only criterion for 
decision -making in this process.  Nevertheless, the investigators will keep the issue of multiple 
comparisons in mind when interpreting the data and making decisions, even though no formal 
adjustm ent is made.    
Analyzable Subjects . All vaccinated subjects will be included in the reactogenicity analysis even 
if they have missing data points.  All vaccinated subjects will be included in the immunogenicity 
analysis if they donated at least one pre -vaccination and one post -vaccination specimen.    
COVID -19. For participants in Cohort C, COVID -19 testing (both PCR and antibody) will be 
performed. Because of the potential for COVID -19 infection (either acute infection or recent prior 
infection) to alter i mmune responses, there will be the intent to stratify the analysis according to 
positive or negative COVID -19 infection.    
10.3 Go/No -Go Milestones  
A set of criteria are to be defined for the safety and tolerability of each of the dose -escalation 
cohorts (Cohor ts A-C or Steps 1 -3), in order to proceed to the next higher dosage cohort.   
Any dose of vaccine which results in more than one episode of a grade 2 or higher solicited 
local or systemic adverse event of the same category, may be considered too reactogeni c for 
dose-escalation, unless the SMC recommends otherwise.  
A set of a priori  safety and immunologic benchmarks for the dose -selection of the vaccine s in 
Part 2 of the  study (Cohort D) is defined. The highest well tolerated dosage ( no more than one  
grade 2 or higher solicited symptom  of the same category ) will be selected for further evaluation 
in Part 2 of the study.  Furthermore, the serum antigen -specific ELISA IgG response rates will 
also be evaluated for dosage selection.  Optimally, t he final targeted dosage will result in at 
least 70% response rates with the target dosage of vaccine.  
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 48 - 11 ETHICS/PROTECTION OF HUMAN SUBJECTS  
11.1 Ethical Standard  
The principal investigator will ensure that this trial is conducted in full conformity with the 
principles of the Bellmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research  of the National Commission for the Protect ion of Human Subjects of 
Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR 46, 21 CFR 50 
and 56, and ICH E6; 62 Federal Regulations 25691 (1997), if applicable.  The principle 
investigator’s institution (University of Maryland, Bal timore , UMB ) will hold a current Federal 
Wide Assurance (FWA) issued by the Office of Human Research Protection (HRPO).  
11.2 Institutional Review Board  
The local institution must provide for the review and approval of this protocol and the associated 
informed c onsent documents by an appropriate ethics review committee or Institutional Review 
Board (IRB). Any amendments to the protocol or consent materials must also be approved before 
they are placed into use unless it is in the best interest of the subjects’ saf ety to implement 
changes prior to approval. In both the United States and in other countries, only institutions 
holding a current U. S. Federal -Wide Assurance issued by the Office for Human Research 
Protections (OHRP) may participate.  
Refer to: http://www.hhs.gov/ohrp/assurances/     
Prior to enrollment of subjects into this clinical study, the protocol and the informed consent 
form(s) will be reviewed and approved by the appropriate IRB. Any amendments to  the protocol 
or consent materials will also be reviewed and approved by the appropriate IRB. The responsible 
official for the IRB will sign the IRB letter of approval of the protocol prior to the start of this clinical 
study. Should amendments to the prot ocol be required, the amendments will be submitted to the 
IRB; an IRB letter of approval of the amendment must be obtained prior to acting upon the 
amendment in the protocol.  
The contact information for the local IRB and the Human Research Protections Offi ce (HRPO ) is: 
University of Maryland , Baltimore  
Human Research Protections Office  
620 W. Lexington Street, Second Floor  
Baltimore, MD 21201 , U.S.A.  
Phone 1 -410-706-5037  
11.3 Informed Consent Process  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continues throughout the individual’s study participation.  Extensive discussion of 
risks and possible benefits of this therapy will be provi ded to the participant.  Consent forms 
describing in detail the study, study procedures and risks are given to the potential participant 
and written documentation of informed consent is required prior to starting any study procedure.  
Consent forms will be  IRB-approved and the participant will be asked to read and review the 
document. Upon reviewing the document, the investigator will explain the research study to the 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 49 - participant and answer any questions that may arise.  The participants will sign the infor med 
consent document prior to any procedures being done specifically for the study.  The participant 
should have the opportunity to discuss the study with their surrogates or think about it prior to 
agreeing to participate.  The participant may withdraw co nsent at any time throughout the 
course of the trial.  A copy of the informed consent document will be given to the participant for 
their records.  The rights and welfare of the participant will be protected by emphasizing to them 
that the quality of their  medical care will not be adversely affected if they decline to participate in 
this study  
11.4 Exclusion of Women, Minorities, and Children (Special 
Populations)  
This clinical study will include women, children of 18 years of age and older, and all minorities 
who meet the inclusion/exclusion criteria, regardless of religion, sex, or ethnic background.  
11.5 Subject Compensation  
Thoughtful consideration has been made toward subject compensation for healthy volunteer 
participants enrolled into clinical studi es involving non -licensed vaccines and experimental 
infections. The overarching ethical issues which the CVD’s compensation scheme attempts to 
address are: (1) avoidance of “undue inducement”, (2) payments which may result in economically 
disadvantaged pop ulations bearing an overwhelming share of the risks and burdens of research, 
and (3) payments which may violate the ethical norms of the investigator -subject relationship by 
turning it into a commercial relationship. The compensation scheme for this study is adopted from 
the Wage -Payment Model.55 Under the Wage -Payment Model, a participant is assumed to require 
little skill, but does require time, effort, and an expectation of experiencing undesirable or 
uncomfortable procedur es.  Therefore, the CVD’s compensation rates are calculated to 
approximate the hourly wages of an unskilled high -risk laborer. The compensation rate used in 
this study is an standard rate that is used across all of CVD’s clinical research. This compensatio n 
rate is clearly described in the informed consent form and is unlikely to be unduly coercive.  
Subjects at the Pharmaron site will be compensated for their time and participation . 
Subject Confidentiality  
Subject (participant) confidentiality is strictly h eld in trust by the investigators, their staff, and the 
Sponsor.  This confidentiality is extended to cover testing of biological samples and other testing 
in addition to the clinical information relating to participant.  
The study protocol, documentation, data, and all other information generated will be held in strict 
confidence.  No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the sponsor.  
The study monitor or other authori zed representatives of the sponsor may inspect all documents 
and records required to be maintained by the investigator, including but not limited to, medical 
records (office, clinic, or hospital) and pharmacy records for the participants in this study.  Th e 
clinical study site will permit access to such records.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 50 - Participant identity data will be contained in paper study records which will be kept in a locked file 
cabinet and in a secure electronic database, accessible only to authorized users at each clinic al 
site. The study database will be user -restricted and password -protected. The study database will 
identify participants by a coded study Volunteer ID number assigned by clinical site personnel, 
thus participants will not be identified by name.  
Subject co nfidentiality and the limits for access to records is described in the informed consent 
form.  
11.6 Future Use of Stored Specimens  
It is intended that any remaining specimens at the closure of the study will be stored at the CVD 
indefinitely and may be used for further immunological analyses. Participants may choose to have 
their specimens destroyed and must do this in a written request. This is described in the consent 
form.  
 
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 51 - 12 DATA HANDLING AND RECORD KEEPING  
The site principal investigator is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported.  
Source data will be generated by the site and collected on data collection forms.  Source data 
will be entered into a REDCap data management system, managed by the Clinic al and 
Translational Research Informatics Center (CTRIC), University of Maryland School of Medicine. 
REDCap is a secure web -based application for building an electronic database that provides a 
21 CFR Part 11, FISMA, and HIPAA -compliant environment. Qualit y control audits of all key 
safety, laboratory, and clinical data in the database will be made after data entry has been 
completed.  Coexistent medical conditions, adverse events and other medical events will be 
coded using MedDRA dictionary. Concomitant m edications will be coded using WHO -DD 
dictionary. When the database has been declared to be complete and accurate, the database 
will be locked.  Any changes to the database after that time will only be by joint written 
agreement of the study team.  
Data re ported in REDCap are derived from the data collection forms and should be consistent 
with the data collection forms or the discrepancies should be explained.  
The sponsor and/or its designee will provide guidance to the site principal investigators and 
other study personnel on making corrections to the data collection forms . 
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 52 - 13 PUBLICATION POLICY  
All investigators funded by the Wellcome Trust must agree to their Open Access Policy. 
https://wellcome.ac.uk/funding/guidance/open -access -policy  
The Open Access Policy contains the following elements:  
1. Expect authors of research papers, monographs and book chapters to maximize the 
opportunities to make their results available for free  
2. Require electronic copies of any research papers that have been accepted for 
publication in a peer -reviewed journal, and are supported in whole or in part by 
Wellcome Trust fun ding, to be made available through PubMed Central (PMC) and 
Europe PMC as soon as possible and in any event within six months of the journal 
publisher's official date of final publication (similarly, monographs and book chapters 
must be made available thro ugh PMC Bookshelf and Europe PMC with a maximum 
embargo of six months)  
3. Expect Wellcome -funded researchers to select publishing routes that ensure the work is 
available immediately on publication in its final published form, wherever such options 
exist for their publisher of choice and are compliant with our policy  
4. Will provide grantholders with additional funding to cover open access charges, where 
appropriate, in order to meet our requirements  
5. Encourage – and where it pays an open access fee, require – authors and publishers to 
license research papers using the Creative Commons Attribution license (CC -BY) so 
they may be freely copied and re -used (for example, for text - and data -mining purposes 
or creating a translation), provided that such uses are fully a ttributed (CC -BY is also the 
preferred license for monographs and book chapters)  
6. Affirm the principle that it is the intrinsic merit of the work, and not the title of the journal 
or the publisher with which an author's work is published, that should be con sidered in 
making funding decisions.  
Therefore, following completion of this clinical trial, the investigators intend to publish the results 
of this research in a peer -reviewed scientific journal, within 12 months of locking the database. 
The International  Committee of Medical Journal Editors (ICMJE) member journals have adopted 
a trials -registration policy as a condition for publication. This policy requires that all clinical trials 
be registered in a public trials registry, such as ClinicalTrials.gov* ( http://clinicaltrials.gov/ ), 
which is sponsored by the National Library of Medicine.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 53 - 14 REFERENCES  
1. Research CfBEa. Adaptive Designs for Clinical Trials of Drugs and Biologics: Draft 
Guidance for In dustry (document citation: 83 FR 49400, agency/docket no. FDA -2018 -D-
3124). In: U.S. Department of Health and Human Services FaDA, ed. Silver Spring, 
Maryland: U.S. Food and Drug Administration; 2018.  
2. Jones TF, Ingram LA, Cieslak PR, et al. Salmonellosi s outcomes differ substantially by 
serotype. J Infect Dis 2008;198:109 -14. 
3. Barton Behravesh C, Jones TF, Vugia DJ, et al. Deaths associated with bacterial 
pathogens transmitted commonly through food: foodborne diseases active surveillance 
network (FoodN et), 1996 -2005. J Infect Dis 2011;204:263 -7. 
4. Vugia DJ, Samuel M, Farley MM, et al. Invasive Salmonella infections in the United 
States, FoodNet, 1996 -1999: incidence, serotype distribution, and outcome. Clin Infect 
Dis 2004;38 Suppl 3:S149 -56. 
5. Ao TT,  Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. Global burden of 
invasive nontyphoidal Salmonella disease, 2010(1). Emerg Infect Dis 2015;21.  
6. Reddy EA, Shaw AV, Crump JA. Community -acquired bloodstream infections in Africa: a 
systematic review and  meta -analysis. Lancet Infect Dis 2010;10:417 -32. 
7. Tapia MD, Tennant SM, Bornstein K, et al. Invasive Nontyphoidal Salmonella Infections 
Among Children in Mali, 2002 -2014: Microbiological and Epidemiologic Features Guide 
Vaccine Development. Clin Infect Dis 2015;61 Suppl 4:S332 -8. 
8. Kingsley RA, Msefula CL, Thomson NR, et al. Epidemic multiple drug resistant 
Salmonella Typhimurium causing invasive disease in sub -Saharan Africa have a distinct 
genotype. Genome Res 2009;19:2279 -87. 
9. Feasey NA, Hadfield J , Keddy KH, et al. Distinct Salmonella Enteritidis lineages 
associated with enterocolitis in high -income settings and invasive disease in low -income 
settings. Nat Genet 2016;48:1211 -7. 
10. Gordon MA, Graham SM, Walsh AL, et al. Epidemics of invasive Salmon ella enterica 
serovar enteritidis and S. enterica Serovar typhimurium infection associated with 
multidrug resistance among adults and children in Malawi. Clin Infect Dis 2008;46:963 -9. 
11. MacLennan CA, Martin LB, Micoli F. Vaccines against invasive Salmon ella disease: 
current status and future directions. Hum Vaccin Immunother 2014;10:1478 -93. 
12. Simon R, Levine MM. Glycoconjugate vaccine strategies for protection against invasive 
Salmonella infections. Hum Vaccin Immunother 2012;8:494 -8. 
13. Typhoid vaccines: WHO position paper – March 2018. World Health Organization. at 
https://apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1 .) 
14. World H ealth O. Typhoid vaccines: WHO position paper, March 2018 - 
Recommendations. Vaccine 2019;37:214 -6. 
15. Baliban SM, Allen JC, Curtis B, et al. Immunogenicity and Induction of Functional 
Antibodies in Rabbits Immunized with a Trivalent Typhoid -Invasive Nont yphoidal 
Salmonella Glycoconjugate Formulation. Molecules 2018;23.  
16. Baliban SM, Curtis B, Toema D, et al. Immunogenicity and efficacy following sequential 
parenterally -administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in 
infant and adult mice. PLoS Negl Trop Dis 2018;12:e0006522.  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 54 - 17. Baliban SM, Yang M, Ramachandran G, et al. Development of a glycoconjugate vaccine 
to prevent invasive Salmonella Typhimurium infections in sub -Saharan Africa. PLoS 
Negl Trop Dis 2017;11:e0005493.  
18. Simon R, Tennant SM, Wang JY, et al. Salmonella enterica serovar enteritidis core O 
polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection 
against invasive infection with S. enteritidis. Infect Immun 2011;79:4240 -9. 
19. Simon R, W ang JY, Boyd MA, et al. Sustained protection in mice immunized with 
fractional doses of Salmonella Enteritidis core and O polysaccharide -flagellin 
glycoconjugates. PLoS One 2013;8:e64680.  
20. Frasch CE, Kapre SV, Lee CH, Preaud JM. Technical Development of  a New 
Meningococcal Conjugate Vaccine. Clin Infect Dis 2015;61 Suppl 5:S404 -9. 
21. Djingarey MH, Diomande FV, Barry R, et al. Introduction and Rollout of a New Group A 
Meningococcal Conjugate Vaccine (PsA -TT) in African Meningitis Belt Countries, 2010 -
2014. Clin Infect Dis 2015;61 Suppl 5:S434 -41. 
22. Konadu E, Shiloach J, Bryla DA, Robbins JB, Szu SC. Synthesis, characterization, and 
immunological properties in mice of conjugates composed of detoxified 
lipopolysaccharide of Salmonella paratyphi A bound to  tetanus toxoid with emphasis on 
the role of O acetyls. Infect Immun 1996;64:2709 -15. 
23. Konadu EY, Lin FY, Ho VA, et al. Phase 1 and phase 2 studies of Salmonella enterica 
serovar paratyphi A O -specific polysaccharide -tetanus toxoid conjugates in adults,  
teenagers, and 2 - to 4-year-old children in Vietnam. Infect Immun 2000;68:1529 -34. 
24. Verez -Bencomo V, Fernandez -Santana V, Hardy E, et al. A synthetic conjugate 
polysaccharide vaccine against Haemophilus influenzae type b. Science 2004;305:522 -
5. 
25. Schuster O, Sears KT, Ramachandran G, et al. Immunogenicity and protective efficacy 
against Salmonella C2 -C3 infection in mice immunized with a glycoconjugate of S. 
Newport Core -O polysaccharide linked to the homologous serovar FliC protein. Hum 
Vaccin Immun other 2018:1 -9. 
26. Robbins JB, Kubler -Kielb J, Vinogradov E, et al. Synthesis, characterization, and 
immunogenicity in mice of Shigella sonnei O -specific oligosaccharide -core-protein 
conjugates. Proc Natl Acad Sci U S A 2009;106:7974 -8. 
27. Kubler -Kielb J . Conjugation of LPS -derived oligosaccharides to proteins using oxime 
chemistry. Methods Mol Biol 2011;751:317 -27. 
28. Mohan VK, Varanasi V, Singh A, et al. Safety and immunogenicity of a Vi 
polysaccharide -tetanus toxoid conjugate vaccine (Typbar -TCV) in h ealthy infants, 
children, and adults in typhoid endemic areas: a multicenter, 2 -cohort, open -label, 
double -blind, randomized controlled phase 3 study. Clin Infect Dis 2015;61:393 -402. 
29. Burki T. Typhoid conjugate vaccine gets WHO prequalification. Lancet  Infect Dis 
2018;18:258.  
30. Insert P. Typhoid (Vi Capsular Polysaccharide) -Tetanus Toxoid Conjugate Vaccine. In: 
Bharat Biotech Inernational L, ed.2017.  
31. Didierlaurent A, Ferrero I, Otten LA, et al. Flagellin promotes myeloid differentiation 
factor 88 -dependent development of Th2 -type response. J Immunol 2004;172:6922 -30. 
32. Vijay -Kumar M, Carvalho FA, Aitken JD, Fifadara NH, Gewirtz AT. TLR5 or NLRC4 is 
necessary and sufficient for promotion of humoral immunity by flagellin. Eur J Immunol 
2010;40:3528 -34. 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 55 - 33. Treanor JJ, Taylor DN, Tussey L, et al. Safety and immunogenicity of a recombinant 
hemagglutinin influenza -flagellin fusion vaccine (VAX125) in healthy young adults. 
Vaccine 2010;28:8268 -74. 
34. Taylor DN, Treanor JJ, Sheldon EA, et al. Developmen t of VAX128, a recombinant 
hemagglutinin (HA) influenza -flagellin fusion vaccine with improved safety and immune 
response. Vaccine 2012;30:5761 -9. 
35. Turley CB, Rupp RE, Johnson C, et al. Safety and immunogenicity of a recombinant 
M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011;29:5145 -
52. 
36. Canh DG, Lin FY, Thiem VD, et al. Effect of dosage on immunogenicity of a Vi conjugate 
vaccine injected twice into 2 - to 5-year-old Vietnamese children. Infect Immun 
2004;72:6586 -8. 
37. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non -
typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. 
Lancet 2012;379:2489 -99. 
38. Ramachandran G, Boyd MA, MacSwords J, et al. Opsonophagocytic Assay To E valuate 
Immunogenicity of Nontyphoidal Salmonella Vaccines. Clin Vaccine Immunol 
2016;23:520 -3. 
39. Wahid R, Zafar SJ, McArthur MA, Pasetti MF, Levine MM, Sztein MB. Live oral 
Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce 
opsonophagoc ytic functional antibodies in humans that cross -react with S. Paratyphi A 
and S. Paratyphi B. Clin Vaccine Immunol 2014;21:427 -34. 
40. Lindow JC, Fimlaid KA, Bunn JY, Kirkpatrick BD. Antibodies in action: role of human 
opsonins in killing Salmonella enteri ca serovar Typhi. Infect Immun 2011;79:3188 -94. 
41. Boyd MA, Tennant SM, Saague VA, et al. Serum bactericidal assays to evaluate 
typhoidal and nontyphoidal Salmonella vaccines. Clin Vaccine Immunol 2014;21:712 -21. 
42. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vaccine Ty21a 
induces cross -reactive humoral immune responses against Salmonella enterica serovar 
Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol 2012;19:825 -34. 
43. Simon JK, Maciel M, Jr., Weld ED, e t al. Antigen -specific IgA B memory cell responses 
to Shigella antigens elicited in volunteers immunized with live attenuated Shigella 
flexneri 2a oral vaccine candidates. Clin Immunol 2011;139:185 -92. 
44. Simon JK, Wahid R, Maciel M, Jr., et al. Antigen -specific B memory cell responses to 
lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers 
vaccinated with live -attenuated Shigella flexneri 2a vaccine candidates. Vaccine 
2009;27:565 -72. 
45. Wahid R, Simon JK, Picking WL, Kotl off KL, Levine MM, Sztein MB. Shigella antigen -
specific B memory cells are associated with decreased disease severity in subjects 
challenged with wild -type Shigella flexneri 2a. Clin Immunol 2013;148:35 -43. 
46. Fresnay S, McArthur MA, Magder LS, et al. Imp ortance of Salmonella Typhi -Responsive 
CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model. Front Immunol 
2017;8:208.  
47. Wahid R, Fresnay S, Levine MM, Sztein MB. Cross -reactive multifunctional CD4+ T cell 
responses against Salmonella enterica s erovars Typhi, Paratyphi A and Paratyphi B in 
humans following immunization with live oral typhoid vaccine Ty21a. Clin Immunol 
2016;173:87 -95. 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 56 - 48. Fresnay S, McArthur MA, Magder L, et al. Salmonella Typhi -specific multifunctional 
CD8+ T cells play a domina nt role in protection from typhoid fever in humans. J Transl 
Med 2016;14:62.  
49. McArthur MA, Fresnay S, Magder LS, et al. Activation of Salmonella Typhi -specific 
regulatory T cells in typhoid disease in a wild -type S. Typhi challenge model. PLoS 
Pathog 20 15;11:e1004914.  
50. Toapanta FR, Bernal PJ, Fresnay S, et al. Oral Wild -Type Salmonella Typhi Challenge 
Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals Who 
Develop Typhoid Disease. PLoS Negl Trop Dis 2015;9:e0003837.  
51. Daga n R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: A 
review. Vaccine 2010;28:5513 -23. 
52. Rappuoli R. Glycoconjugate vaccines: Principles and mechanisms. Sci Transl Med 
2018;10.  
53. Huebner RE, Mbelle N, Forrest B, Madore DV, Klu gman KP. Immunogenicity after one, 
two or three doses and impact on the antibody response to coadministered antigens of a 
nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr 
Infect Dis J 2002;21:1004 -7. 
54. Deloria Knoll M , Park DE, Johnson TS, et al. Systematic review of the effect of 
pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect 
Dis J 2014;33 Suppl 2:S119 -29. 
55. Dickert N, Grady C. What's the price of a research subject? Approaches to payment for 
research participation. N Engl J Med 1999;341:198 -203. 
 
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 57 - APPENDIX A: SCHEDULE OF EVENTS  (COHORT A -B) 
Type of Visit  Screen  V F F F F F 
 Study Day  -45 to -2 1 2 8 29 57 180 
Window     ±1 ±3 ±3 ±14 
Informed Consent  X X      
Review Eligibility  X X      
Medical History  X X      
Targeted Exam, if indicated  X X      
Vital Signs (temp, HR and BP) X X      
Pregnancy Test  XS XU      
Concomitant Meds  X X      
Randomization   X      
Vaccination   #1      
7-day Memory Aid ( disperse & collect)   d x c    
AE assessment   X X X X   
SAE assessment   X X X X X X 
        
Screening Labs1 16 mL       
Safety Labs2  12.5 mL  3.5 mL  12.5 mL    
Research Blood Draw – serum   15 mL    15 mL  15 mL  15 mL  
Research Blood Draw – PBMC   80 mL   40 mL*  80 mL  80 mL  80 mL  
        
Total cumulative volume of blood, mL  16 123.5  127 139.5  
179.5*  234.5  
274.5*  329.5  
469.5*  424.5  
464.5* 
Outpatient clinic visit: V= Vaccination; F= Follow -up visit;  
Pregnancy testing, by S= Serum pregnancy test; U= Urine pregnancy test  
1 - Screening Laboratory testing will include: 4 mL for Hematology (WBC , ANC, Hemoglobin, Platelet count) ; 10 mL for Chemistry (creatinine, AST, ALT, 
total bilirubin, and C -reactive protein ; inclusive of β-HCG, when indicated ); 5 mL for Serology ( Hepatitis B surface antigen  and Hepatitis C antibody ); 
and 3.5 mL for HIV antibody.  
2 - Clinical Safety Laboratory testing on Day 1 and 8 will include: 4 mL for Hematology (WBC , ANC, Hemoglobin , Platelet count) and 10 mL for Chemistry 
(creatinine, AST, ALT, total b ilirubin, and C -reactive protein ). On Day 2, 3.5 mL for C -reactive protein only.  
* for Cohort B, on the day 8 visit, a 40 mL volume of blood will be drawn for PBMC to allow for ASC and homing studies  
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 58 - APPENDIX A: SCHEDULE OF EVENTS ( COHORT C AND D) 
Type of Visit  Screen  V F F V F F F 
 Study Day  -45 to -2 1 2 8 29 36 57 210 
Window     ±1 ±3 ±1 ±3 ±14 
Informed Consent  X X   X    
Review Eligibility  X X   X    
Medical History  X X   X    
Targeted Exam, if indicated  X X   X    
Vital Signs (temp, HR and BP) X X   X    
Pregnancy Test  XS XU   XU    
Concomitant Meds  X X   X    
Randomization   X       
Vaccination   #1   #2    
7-day Memory Aid ( disperse & collect)   d x c d c   
AE assessment   X X X X X X  
SAE assessment   X X X X X X X 
Collect oral fluid   X   X  X X 
Collect NP swab, for SARS -CoV-2 PCR test   X   X    
 
Screening Labs1 16 mL        
Safety Labs2  12.5 mL  3.5 mL  12.5  mL     
SARS -CoV-2 antibody test   5 mL    5 mL     
Research Blood Draw – serum   15 mL    15 mL   15 mL  15 mL 
Research Blood Draw – PBMC   80 mL   40 mL  80 mL  40 mL  80 mL  80 mL  
         
Total cumulative volume of blood, mL  16 128.5 132 184.5 284.5 324.5 419.5 514.5 
Outpatient clinic visit: V= Vaccination; F= Follow -up visit;  
Pregnancy testing, by S= Serum pregnancy test; U= Urine pregnancy test  
1 - Screening Laboratory testing will include: 4 mL for Hematology (WBC, ANC, Hemoglobin, Platelet count); 10 mL for Chemistry (c reatinine, AST, ALT , 
total bilirubin, and C -reactive protein; inclusive of β-HCG, when indicated); 5 mL for Serology (Hepatitis B surface antigen and Hepatitis C antibody); 
and 3.5 mL for HIV antibody.  
2 - Clinical Safety Laboratory testing on Day 1 and 8 will include: 4 mL  for Hematology (WBC, ANC, Hemoglobin, Platelet count) and 8.5 mL for 
Chemistry (creatinine, AST, ALT, total bilirubin, and C -reactive protein) . On Day 2, 3.5 mL for C -reactive protein only.  
NP= nasopharyngeal swab  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 59 - APPENDIX B: CLINICAL LABORATORY VALUES, FOR STUDY ELIGIBILITY  
Laboratory Parameter  Units of measure  Reference Range * Study Inclusion  
Total white blood cell count, WBC  cells x103 / mm3 4.0 – 10.0  3.0 – 11.5  
Absolute Neutrophil Count, ANC  cells / mm3 1560 – 8100  1100 – 8910  
Hemoglobin, Hg (male)  gram / dL  13.5 – 17.5  11.0 – 17.6  
Hemoglobin, Hg (female)  gram / dL  12.0 – 16.0  10.3 – 17.6  
Platelet count  platelet x 103 / mm3 130 - 400 125 - 480 
Creatinine (male)  mg / dL  0.7 – 1.3 <1.4  
Creatinine (female)  mg / dL  0.6 – 1.1 <1.2  
Alanine aminotransferase, ALT  U / L  7-45 <68 
Aspartate aminotransferase, AST (male)  U / L  15 – 40 <60 
Aspartate aminotransferase, AST (female)  U / L  13 - 30 <45 
Total bilirubin  mg/dL  0.2 – 1.2 <1.5  
C-reactive protein  mg/dL <0.8  <1.1  
Hepatitis B surface antigen, HBsAg  n/a Negative  Negative  
Hepatitis C Virus antibody  n/a Non-reactive  Non-reactive  
Human Immunodeficiency Virus antibody  n/a Non-reactive  Non-reactive  
 
* The reference ranges provided are from Garcia Labs, published from 28 July 2016.  
 
 
  
Salmonella conjugates CVD 1000   v10.0: 25 February  2021   
 
_____________________________________________________________________________________________  
  - 60 - APPENDIX C : GRADING SCALES FOR LABORATORY TOXICITY  AND 
REACTOGENICITY  
Parameter  Mild, Grade 1  Moderate, Grade 2  Severe, Grade 3  
WBC, high  (cells x103/mm3) 11.5 – 13.0 13.1 – 15.0 > 15.0 
WBC, low  (cells x103/mm3) 2.5 – 3.0 1.5 – 2.4 < 1.5 
ANC, high  (cells/mm3) 8900 – 10,000  10,010 – 12,000  > 12,000 
ANC, low  (cells/mm3) 800 - 1000 600 - 799 < 600  
Hemogloblin , high  (gram/dL)  < 1.2 x ULN  1.2-1.5 x ULN  > 1.5 x ULN  
Hemogloblin, low  (gram/dL)  > 0.8 x LLN  0.8 – 0.7 x LLN  < 0.7 x LLN  
Platelets, high   (x 103/mm3) < 1.3 x ULN  1.3-1.6 x ULN  > 1.6 x ULN  
Platelets, low  (x 103/mm3) > 0.9 x LLN  0.7-0.9 x LLN  < 0.7 x LLN  
Creatinine, high   (mg/dL)  < 1.3 x ULN  1.3-1.8 x ULN  >1.8 x ULN  
ALT, high  (U/L)  < 2.5 x ULN  2.5-5.0 x ULN  > 5.0 x ULN  
AST, high  (U/L)  < 2.5 x ULN  2.5-5.0 x ULN  > 5.0 x ULN  
Total bilirubin  < 2.0 x ULN  2.0-5.0 x ULN  > 5.0 x ULN  
C-reactive protein  < 2.0 x ULN  2.0-5.0 x ULN  > 5.0 x ULN  
 
Pain, Injection site  Minimal limitation of limb use  Greater than minimal 
limitation of limb use  Inability to use limb or 
perform daily activities  
Erythema, Injection site * < 5 cm  5 - 10 cm  > 10 cm  
Ecchymosis, Injection site  < 5 cm  5 - 10 cm  > 10 cm  
Induration, Injection site  < 5 cm  5 - 10 cm  > 10 cm  
 
Chills  
No interference with daily 
activity  Some interference with daily 
activity  Significant interference, 
prevents daily activity  Fatigue  
Headache  
Malaise  
Myalgia  
Arthralgia  
Nausea  
Oral temperature  (fever)  100.0 – 101.1 °F 101.2 – 102.0 °F > 102 °F 
ULN – upper limit of normal ; LLN – lower limit of normal  
* Injection site erythema will not count toward a halting rule.  Injection site erythema of any size with ulceration, drainag e, sterile abscess, or evidence 
of secondary infection should be recorded as an AE  